

Award Number: W81XWH-11-2-0046

TITLE: "Role of Adenosine Receptor A2A in Traumatic Optic Neuropathies"

PRINCIPAL INVESTIGATOR: Gregory I. Liou, PhD

CONTRACTING ORGANIZATION: Georgia Health Sciences University
Augusta, GA 30912-4810

REPORT DATE: March 2016

TYPE OF REPORT: Addendum to Final

PRE PARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE March 2016		2. REPORT TYPE Addendum to Final		3. DATES COVERED 1Dec2014 - 31Dec2015	
4. TITLE AND SUBTITLE "Role of Adenosine Receptor A2A in Traumatic Optic Neuropathies"				5a. CONTRACT NUMBER W81XWH-11-2-0046	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Gregory I. Liou, PhD; Saif Ahmad, PhD; Mohammad Naime, PhD; Nadeem Fatteh, MD; Sohail Khan, MD E-Mail: giliou@georgiahealth.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgia Health Sciences University 1120 15th Street, CJ3301 Augusta, GA 30912-4810				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This report summarizes the research progress and outcome of Traumatic optic neuropathy (TON). The report describes that TON as a vision-threatening complication in head injury in the war. Our goal is to develop an early therapeutic intervention before the progression of TON becomes irreversible. To achieve this goal, we tested the hypothesis that increase in the extracellular levels of adenosine can offer such an intervention. Under the stress of TON, extracellular levels of adenosine increase due to its increased formation by ecto-5'-nucleotidase or decreased metabolism by the intracellular adenosine kinase. Extracellular adenosine is then increased through equilibrative nucleoside transporter and activates an endogenous anti-inflammation through a receptor-mediated pathway. This lab is currently engaged in the discovery of an adenosine kinase inhibitor, which can be used to inhibit TON-induced tissue damage.					
15. SUBJECT TERMS Traumatic optic neuropathy, adenosine receptor A2A, microglia, inflammation, adenosine kinase, ecto-5'-nucleotidase					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	37	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	6
Appendices.....	7

INTRODUCTION

Since 2011, our lab has been involved in the mechanism of traumatic optic neuropathy (TON), a terrible consequence of head concussion during the war that leads to total vision loss if care is delayed. Following traumatic insults to the optic nerve, the surveillance retinal microglial cells are activated through MAPKinase pathways and increased cytotoxic activity that lend toward damage and death of neighboring and otherwise unharmed retinal ganglion cells (RGCs), further exacerbating the degenerative process. Under the stress of TON, extracellular concentration of adenosine is likely to increase due to its increased formation by ecto-5'-nucleotidase (CD73) (Ernst *et al.*, 2010) or decreased metabolism by the intracellular adenosine kinase (AK) (Löffler *et al.*, 2007). The accumulated intracellular adenosine is then released through equilibrative nucleoside transporter (ENT). Extracellular adenosine activates an anti-inflammatory pathway through adenosine receptor A2AAR (Bong *et al.*, 1996; Ralevic and Burnstock, 1998). TON-induced retinal inflammation is likely due to an imbalance in adenosine formation and metabolism. However, we do not know the relative contribution of AK and CD73 in causing this imbalance. We have demonstrated that hypoxia-induced microglia activation was inhibited by inhibitors of MAPKinases (ERK and P38) and AK. We have also shown that hypoxia-induced CD73 up-regulation suppressed microglia activation. Based on these findings, we tested the hypothesis in an *in vivo* model of TON that at least adenosine metabolism by AK contributed to this imbalance.

BODY

A. Statement of work

We seek to understand the mechanism of inflammation in TON in an effort to control RGC death.

Task 1: To test the hypothesis that A2AAR-cAMP signaling is anti-inflammatory in TON.

Task 2: To test the hypothesis that anti-inflammation by A2AAR-cAMP signaling is impaired in TON.

B. Hypotheses to be tested

Hypothesis 1. We hypothesize that a mechanism of anti-inflammation mediated by A2AAR signaling exists in retinal microglial cells. In the setting of TON, however, this process is overwhelmed by the pro-inflammatory state. We further hypothesize that a selective A2AAR agonist effective in reducing inflammation in other disease processes is of utility in TON.

Hypothesis 2. We hypothesize that an imbalance in adenosine formation and metabolism in the retinal microglia participated by AK may contribute significantly to retinal complications in the setting of TON.

C. Experimental Design and Results

Hypothesis 1.

Methods. Mice were anesthetized according to standard protocol and bilateral limbal conjunctival peritomy was performed posteriorly to the optic nerve in each mouse. Compression by forceps was performed on the right optic nerve in each mouse with the left optic nerve serving as a control. Compression was released at 10 seconds and pupillary dilation was noted. Mice were treated with or without an A2AAR agonist, CGS21680 (25µg/kg; i. p.) every other day for 7 days. All retinas were then harvested.

Results. In all the nerve crush model of TON, it was clear that microglial cells were mostly activated. In this model, treatment with A2AAR activator (agonist) inhibited the expression of these antigens. It is important to note that, administration of A2AAR activator showed no effect in control model.

Problem Area. We do not know whether the limited adenosine availability in stressed cells or in TON is due to increased adenosine metabolism by AK or decreased adenosine formation by CD73, or both.

Hypothesis 2.

Methods. Mice were anesthetized according to standard protocol and bilateral limbal conjunctival peritomy was performed posteriorly to the optic nerve in each mouse. Compression by forceps was performed on the right optic nerve in each mouse with the left optic nerve serving as a control. Compression was released at 10 seconds and pupillary dilation was noted. Mice were treated with or without an AK inhibitor (AKI), ABT702 (25µg/kg; i. p.), every other day for 7 days. All retinas were then harvested for RNA preparation. Gene expression was determined by Real-Time PCR analysis.

Results. In a series experiments with Real-Time PCR, increased expression of TNF- α , Iba1, and caspase3 were shown in nerve crush model. In subgroup of nerve crush model that was treated with AKI, lower expression was noted. It was also noted that administration of AKI showed no effect in the control.

Problem Area. Although the results suggest that the limited adenosine availability in TON is due to the activity of AK, we do not know whether CD73 also plays a role.

D. KEY RESEARCH ACCOMPLISHMENTS

1. Our results suggest that TON can be effectively treated with selective adenosine receptor agonist which ameliorates inflammation by activating A2AAR, thereby reducing microglial activity.
2. Our results suggest that TON can also be effectively treated with selective inhibitors for MAPKinases, which ameliorate inflammation by reducing microglial activity.
3. Our results suggest that TON can also be effectively treated with an inhibitor for AK, which ameliorates inflammation by reducing microglial activity.

E. REPORTABLE OUTCOMES

This research has resulted in three presentations in a scientific meeting (ARVO) and three peer-reviewed papers.

F. CONCLUSION

Optic nerve injury-induced retinal degeneration can be effectively treated with selective adenosine receptor agonists, selective inhibitors for MAPKinases, or inhibitor for AK. All of these ameliorate inflammation by reducing microglial activity.

G. REFERENCES

Bong, G.W., S. Rosengren, and G.S. Firestein, Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors. *J Clin Invest*, 1996. 98(12): p. 2779-85.

Ernst PB, Garrison JC, Thompson LF (2010). Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology. *J Immunol* 185: 1993–1998.

Löffler M, Morote-Garcia JC, Eltzhig SA, Coe IR, Eltzhig HK (2007). Physiological roles of vascular nucleoside transporters. *Arterioscler Thromb Vasc Biol* 27: 1004-1013.

Ralevic, V. and G. Burnstock, Receptors for purines and pyrimidines. *Pharmacol Rev*, 1998. 50(3): p.413-92.

APPENDIX

Abstracts

1) Ahmad S, Fatteh N, El-Sherbiny NM, Naime M, Ibrahim AS, El-Sherbini AM, El-Shafey SA, Khan S, Fulzele S, Gonzales J, Liou GI. Potential role of A2A adenosine receptor in traumatic optic neuropathy. *J Neuroimmunol.* 2013 Nov 15;264(1-2):54-64. doi: 10.1016/j.jneuroim.2013.09.015. Epub 2013 Sep 21. PMID:24090652

In traumatic optic neuropathy (TON), apoptosis of retinal ganglion cells is closely related to the local production of reactive oxygen species and inflammatory mediators from activated microglial cells. Adenosine receptor A2A (A2AAR) has been shown to possess anti-inflammatory properties that have not been studied in TON. In the present study, we examined the role of A2AAR in retinal complications associated with TON. Initial studies in wild-type mice revealed that treatment with the A2AAR agonist resulted in marked decreases in the TON-induced microglial activation, retinal cell death and releases of reactive oxygen species and pro-inflammatory cytokines TNF- α and IL-6. To further assess the role of A2AAR in TON, we studied the effects of A2AAR ablation on the TON-induced retinal abnormalities. A2AAR^{-/-} mice with TON showed a significantly higher mRNA level of TNF- α , Iba1-1 in retinal tissue, and ICAM-1 expression in retinal sections compared with wild-type mice with TON. To explore a potential mechanism by which A2AAR-signaling regulates inflammation in TON, we performed additional studies using hypoxia- or LPS-treated microglial cells as an in vitro model for TON. Activation of A2AAR attenuates hypoxia or LPS-induced TNF- α release and significantly repressed the inflammatory signaling, ERK in the activated microglia. Collectively, this work provides pharmacological and genetic evidence for A2AAR signaling as a control point of cell death in TON and suggests that the retinal protective effect of A2AAR is mediated by attenuating the inflammatory response that occurs in microglia via interaction with MAPKinase pathway.

2) Ahmad S, Elsherbiny NM, Bhatia K, Elsherbini AM, Fulzele S, Liou GI. Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy. *J Neuroimmunol.* 2014 Dec 15;277(1-2):96-104. doi: 10.1016/j.jneuroim.2014.10.006. Epub 2014 Oct 22. PMID:25457840

Traumatic optic neuropathy (TON) is associated with apoptosis of retinal ganglion cells. Local productions of reactive oxygen species and inflammatory mediators from activated microglial cells have been hypothesized to underlie apoptotic processes. We previously demonstrated that the anti-inflammatory effect of adenosine, through A2A receptor activation had profound protective influence against retinal injury in traumatic optic neuropathy. This protective effect is limited due to rapid cellular re-uptake of adenosine by equilibrative nucleoside transporter-1 (ENT1) or break down by adenosine kinase (AK), the key enzyme in adenosine clearance pathway. Further, the use of adenosine receptors agonists are limited by systemic side effects. Therefore, we seek to investigate the potential role of amplifying the endogenous ambient level of adenosine by pharmacological inhibition of AK. We tested our hypothesis by comparing TON-induced retinal injury in mice with and without ABT-702 treatment, a selective AK inhibitor (AKI). The retinal-protective effect of ABT-702 was demonstrated by significant reduction of Iba-1, ENT1, TNF- α , IL-6, and iNOS/nNOS protein or mRNA expression in TON as revealed by western blot and real time PCR. TON-induced superoxide anion generation and nitrotyrosine expression were reduced in ABT-702 treated mice retinal sections as determined by immunofluorescence. In addition, ABT-702 attenuated p-ERK1/2 and p-P38 activation in LPS induced activated mouse microglia cells. The results of the present investigation suggested that ABT-702 had a protective role against marked TON-induced retinal inflammation and damage by augmenting the endogenous therapeutic effects of site- and event-specific accumulation of extracellular adenosine.

3) Elsherbiny NM, Ahmad S, Naime M, Elsherbini AM, Fulzele S, Al-Gayyar MM, Eissa LA, El-Shishtawy MM, Liou GI. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. *Life Sci.* 2013 Jul 30;93(2-3):78-88. doi: 10.1016/j.lfs.2013.05.024. Epub 2013 Jun 12. PMID:23770229

AIMS:

This study was undertaken to determine the effect of an adenosine kinase inhibitor (AKI) in diabetic retinopathy (DR). We have shown previously that adenosine signaling via A2A receptors (A2AAR) is involved in retinal protection from diabetes-induced inflammation. Here we demonstrate that AKI-enhanced adenosine signaling provides protection from DR in mice.

MAIN METHODS:


We targeted AK, the key enzyme in adenosine metabolism, using a treatment regime with the selective AKI, ABT-702 (1.5mg/kg intraperitoneally twice a week) commencing at the beginning of streptozotocin-induced diabetes at the age of eight weeks. This treatment, previously demonstrated to increase free adenosine levels in vivo, was maintained until the age of 16 weeks. Retinal inflammation was evaluated using Western blot, Real-Time PCR and immuno-staining analyses. Role of A2AAR signaling in the anti-inflammation effect of ABT-702 was analyzed in Amadori-glycated-albumin (AGA)-treated microglial cells.

KEY FINDINGS:

At 16 weeks, when diabetic mice exhibit significant signs of retinal inflammation including up-regulation of oxidative/nitrosative stress, A2AAR, ENT1, Iba1, TNF- α , ICAM1, retinal cell death, and down-regulation of AK, the ABT-702 treated group showed lower signs of inflammation compared to control animals receiving the vehicle. The involvement of adenosine signaling in the anti-inflammation effect of ABT-702 was supported by the TNF- α release blocking effect of A2AAR antagonist in AGA-treated microglial cells.

SIGNIFICANCE:

These results suggest a role for AK in regulating adenosine receptor signaling in the retina. Inhibition of AK potentially amplifies the therapeutic effects of site- and event-specific accumulation of extracellular adenosine, which is of highly translational impact.



Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy

Saif Ahmad^{a,b,*}, Nehal M. Elsherbiny^{a,c}, Kanchan Bhatia^b, Ahmed M. Elsherbini^a,
Sadanand Fulzele^d, Gregory I. Liou^{a,**}

^a Department of Ophthalmology, School of Medicine, Georgia Regents University (GRU), Augusta, GA, USA

^b Department of Biological Sciences, Rabigh College of Science and Arts, King Abdulaziz University, Rabigh, Saudi Arabia

^c Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

^d Department of Orthopedics, Georgia Regents University (GRU), Augusta, GA, USA

ARTICLE INFO

Article history:

Received 17 June 2014

Received in revised form 3 October 2014

Accepted 15 October 2014

Keywords:

Traumatic optic neuropathy

Adenosine kinase

ABT-702

Microglia

Inflammation

MAPKinase

ABSTRACT

Traumatic optic neuropathy (TON) is associated with apoptosis of retinal ganglion cells. Local productions of reactive oxygen species and inflammatory mediators from activated microglial cells have been hypothesized to underlie apoptotic processes. We previously demonstrated that the anti-inflammatory effect of adenosine, through A_{2A} receptor activation had profound protective influence against retinal injury in traumatic optic neuropathy. This protective effect is limited due to rapid cellular re-uptake of adenosine by equilibrative nucleoside transporter-1 (ENT1) or break down by adenosine kinase (AK), the key enzyme in adenosine clearance pathway. Further, the use of adenosine receptors agonists are limited by systemic side effects. Therefore, we seek to investigate the potential role of amplifying the endogenous ambient level of adenosine by pharmacological inhibition of AK. We tested our hypothesis by comparing TON-induced retinal injury in mice with and without ABT-702 treatment, a selective AK inhibitor (AKI). The retinal-protective effect of ABT-702 was demonstrated by significant reduction of Iba-1, ENT1, TNF- α , IL-6, and iNOS/nNOS protein or mRNA expression in TON as revealed by western blot and real time PCR. TON-induced superoxide anion generation and nitrotyrosine expression were reduced in ABT-702 treated mice retinal sections as determined by immunofluorescence. In addition, ABT-702 attenuated p-ERK1/2 and p-P38 activation in LPS induced activated mouse microglia cells. The results of the present investigation suggested that ABT-702 had a protective role against marked TON-induced retinal inflammation and damage by augmenting the endogenous therapeutic effects of site- and event-specific accumulation of extracellular adenosine.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Traumatic optic neuropathy (TON) is partial or complete loss of function of optic nerve (ON) due to either a direct injury or indirectly after head trauma sequelae, such as edema, hemorrhage, and concussion (Steinsapir and Goldberg, 2011). Unfortunately, there are currently no proven treatments that can prevent the damage associated with an acute TON. Optic nerve injury mediated loss of retinal ganglion cells (RGCs) through apoptosis has been hypothesized due to several

underlying common mechanisms, including lack of neurotrophin support, increased extracellular glutamate levels, damage from free radicals, and disruption of cellular homeostasis (Pang et al., 2010). All these mechanisms cause activation of microglial cells and inflammatory responses such as release of free radicals, cytokines, and prostaglandins and complement molecules (Lucas et al., 2006). Therefore, counteracting inflammation may possess neuroprotective effect in TON.

Adenosine is a ubiquitous homeostatic purine nucleoside that accumulates extracellularly in response to metabolic stresses such as hypoxia and inflammation. Activation of either G protein-coupled adenosine receptors (ARs; A₁R, A_{2A}R, A_{2B}R, and A₃R) by extracellular adenosine can modulate cell signaling. However, A_{2A} receptor activation significantly modulates neuronal integrity and neuroprotection by adenosine receptor modulation has been demonstrated in several model systems (Lusardi, 2009). In accordance, we have demonstrated that A_{2A}AR signaling had a protective effect in traumatic optic neuropathy by attenuating microglia induced inflammatory response (Ahmad et al., 2013).

ARs agonists have limited therapeutic use due to systemic side effects (Fredholm et al., 2005). However, a promising alternative might

Abbreviations: TON, traumatic optic neuropathy; TNF- α , tumor necrosis factor- α ; ELISA, enzyme-linked immunosorbent assay; ROS, reactive oxygen species; MAP kinase, mitogen-activated protein kinase; ERK, P38, extracellular signal-regulated kinase; AR, adenosine receptor; AKI, adenosine kinase inhibitor; ABT-702, 2-p-[2-Carboxyethyl]phenethylamino-5'-N-ethylcarboxamidoadenosine; LPS, lipopolysaccharides.

* Correspondence to: S. Ahmad, Department of Biological Sciences, Rabigh College of Science and Arts, King Abdulaziz University, Post Box 344, Rabigh-21911, Saudi Arabia. Tel.: +966 594355530.

** Correspondence to: G.I. Liou, Department of Ophthalmology, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA. Tel.: +1 706 721 4599; fax: +1 706 721 1158.

E-mail addresses: asaif77@yahoo.com (S. Ahmad), giliou@gru.edu (G.I. Liou).

be the augmentation of the adenosine levels by targeting enzymes or nucleoside transporters that regulate the extracellular levels of adenosine (Shen et al., 2012). Metabolic clearance of adenosine occurs through key enzyme adenosine kinase (ADK) and evidence shows that the inhibition of this enzyme increases extracellular adenosine levels in cell and tissues (Boison and Shen, 2010). Indeed, the inhibition of ADK has been proven to possess potential therapeutic usefulness in a wide range of neurological disorders (Boison, 2008). In this context, we previously reported that pharmacologic inhibition of ADK augments adenosine and exerts activity in retina of diabetic mice (Elsherbiny et al., 2013). Here, we seek to investigate the retinal protective role of ABT-702, a selective adenosine kinase inhibitor against marked TON-induced retinal inflammation and damage.

2. Materials and methods

2.1. Experimental design

All procedures with animals were performed in accordance with the Public Health Service Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and Welfare publication, NIH 80-23) and Georgia Regents University, Augusta, GA, USA guidelines. Eightto tenweek-old male wild-type (WT) mice (16 mice in each group) in C57BL/6 background were used for experiments. Mice were anesthetized according to standard protocol and limbal conjunctival peritomy was performed on one eye of each mouse. Forceps dissection under the conjunctiva posteriorly allowed access to the optic nerve, upon which pressure was placed 1 mm posterior to the globe until pupillary dilation was noted (approximately 10 s). Blood vessel close to optic nerve was carefully avoided in TON surgery. Mock-operated contra lateral eye served as the control. After one week, all mice were sacrificed. Eyes were enucleated and sectioned for histological analysis. Retinas were harvested for Western or Real Time PCR analysis. In pharmacologic studies, age-, weight- and sex-matched C57BL/6 mice were rendered optic nerve crush and then injected i.p. with vehicle (DMSO), or ABT-702 (AKI, Adenosine Kinase Inhibitor) (1.5 mg/kg bwt, i.p.) every other day for the duration of the study (n = 4–6/group).

2.2. Western blot analysis

Protein expression was measured by western blotting. In brief, washed cultured cells or retinal tissues were lysed in modified RIPA buffer (Upstate, Lake Placid, NY), containing 50 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic acid, 1% Nonidet P-40, 0.25% deoxycholate, supplemented with 40 mmol/L NaF, 2 mmol/L Na₃VO₄, 0.5 mmol/L phenylmethylsulfonyl fluoride and 1:100 (v/v) of proteinase inhibitor cocktail (Sigma). Insoluble material was removed by centrifugation at 12,000 × g at 4 °C for 30 min. Protein was determined by Bradford method (Bio-Rad, Hercules, CA). 50–100 µg was boiled in Laemmli sample buffer, separated by SDS-PAGE on a gradient gel (4 to 20%) (Pierce, Rockford, IL), transferred to nitrocellulose membrane and incubated with specific antibodies. Antibodies for β-actin (Sigma), Iba1 (Wako, Japan), ADK, iNOS, nNOS, nitrotyrosine and ENT1 from Santa cruz Biotechnology Inc., CA, and phospho-ERK and ERK (Cell Signaling Technology, Beverly, MA) were detected with a horseradish peroxidase-conjugated antibody and ECL chemiluminescence (Amersham BioSciences, Buckinghamshire, UK). Intensity of immunoreactivity was measured by densitometry.

2.3. Immunohistochemical analysis

Immunofluorescence analysis was performed using frozen retinal sections. Briefly, cryostat sections (10 µm) were fixed in 4% paraformaldehyde, blocked with 10% normal goat serum (NGS) and then incubated overnight at 4 °C with primary antibodies: Rabbit anti-nitrotyrosine, rabbit anti-Iba-1 (Wako Pure Chemical, Wako, TX), or mouse anti-

pERK1/2 antibody (Cell signaling technology, USA). Thereafter, sections were briefly washed with 1X PBS-T (0.1%) or 0.3% Triton X-100 and incubated with appropriate secondary antibodies (Invitrogen). Slides were examined under the fluorescence microscope (Carl Zeiss). Specificity of the reaction was confirmed by omitting the primary antibody. Data (10 fields/retina, n = 4–6 in each group) were analyzed using fluorescence microscopy and Ultra-View morphometric software or Image J software (NIH) to quantify the intensity of immunostaining.

2.4. Real-time PCR (isolation of RNA, synthesis of cDNA)

Total RNA was isolated from mouse retina using SV Total RNA Isolation kit (Promega, Madison, WI) following manufacturer's instructions, and the quality of the RNA preparations was monitored by absorbance at 260 and 280 nm (Helios-Gamma, Thermo Spectronic, Rochester, NY). The RNA was reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using iScript reagents from Bio-Rad in a programmable thermal cycler (PCR-Sprint, Thermo Electron, Milford, MA). 50 ng of cDNA was amplified in each real-time PCR using Bio-Rad iCycler, ABgene reagents (Fisher scientific) and appropriate primers (Table 1). An average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA was used as the internal control for normalization.

2.5. Analysis of dihydroethidium (DHE) fluorescence for the detection of superoxide

The detection of superoxide anion in the mouse eye sections was performed as described previously (Ahmad et al., 2013). In brief, mouse eyes were frozen in OCT and stored at −80 °C until use. Enzymatically intact eye sections were thawed in room temperature, rehydrated with PBS, incubated with dihydroethidium (DHE; 10 µmol/L in PBS) for 30 min at 37 °C in a humidified chamber protected from light. After incubation, sections were washed with PBS. DHE is oxidized on reaction with superoxide to ethidium, which binds to DNA in the nucleus and emits red fluorescence. For the detection of ethidium, samples were examined with a fluorescence microscope (Axioskop 2 plus with AxioCam; Carl Zeiss, Germany; Excitation/Emission wavelengths: 518/605 nm). DHE fluorescence was quantified using Image J software (NIH).

2.6. Mouse microglia cell culture, drugs treatment

The mouse microglial cell line EOC-20 was obtained from the American Type Culture Collection (ATCC CRL-2469, Manassas, VA, USA). Cells were maintained at 37 °C and 5% CO₂ in DMEM supplemented with 10% fetal bovine serum, 0.5% penicillin/streptomycin, 4 mM L-glutamine, and 20% conditioned medium from bone-marrow-derived Ladam cells (ATCC CRL-2420) as a source of colony stimulating

Table 1

The primer sets used for the detection of mouse genes by quantitative real-time PCR analysis.

Gene	Primer sequence (5'-3')	Accession number
TNF-α	CCCTCACACTCAGATCATCTTCT GTCACGACGTGGGCTACAG	NM_013693.2
ENT1	CAAGTATTTTCAAAACCGCTGGAC GAAACGAGTTGAGGCGAGTGAAGAC	Am J Physiol Heart Circ Physiol 299:H847–H856, 2010
Iba-1	GTCTTGAAGCGAATGCTGG CATTCTCAAGATGGCAGATC	NM_019467
iNOS	ACA TCG ACC CGT CCA CAG TAT CAG AGG GGT AGG CTT GTC TC	Primer Bank ID 6754872
IL-6	TAGTCCTTCTACCCCAATTTC TTGGTCCTTAGCCACTCCTTC	NM_031168.1
GAPDH	CAT GGC CTC CAA GGA GTAAGAGAG GGA GAT GCT CAG TGT TGG	M32599
18S	AGT GCG GGT CAT AAG CTT GC GGG CCT CAC TAA ACC ATC CA	NR_003278

factor-1. EOC-20 cells were grown to 60% confluence at which point their media were removed and replaced with fresh medium. Microglial cells were seeded in a 6-well tissue culture plate. One day after seeding, the wells were washed with DMEM and incubated in the same media with various treatments. Cells were pretreated with ABT-702 (AKI-20 μ M, Tocris, Ellisville, MO), SB203580 (P38 inhibitor, 20 μ M) and U0126 (MEK inhibitor, 20 μ M) at the indicated concentrations reported previously or vehicle dimethylsulfoxide (DMSO) for 30 min at 37 °C before LPS (50 ng/ml for 24 h) treatment. At indicated time points, cells were harvested and homogenized for Western blot analysis and culture media were taken and analyzed for TNF- α by ELISA. For immunocytochemistry, mouse microglia cells were grown in 4 well chambers and after the drug treatment and indicated time point cells were fixed in 4% paraformaldehyde for 20 min and then washed with PBS and the slides were stored at 4 °C for immunofluorescence study.

2.7. Enzyme-linked immunosorbent assay (ELISA) for TNF- α

TNF- α levels in the supernatants of culture media were estimated with ELISA kits (R&D, Minneapolis, MN) as per the manufacturer's instructions. Standards and samples were added and bound by the immobilized antibody. After washing, an enzyme-linked polyclonal antibody specific for the cytokine was added to the wells followed by a substrate solution yielding a colored product. The intensity of the color was measured at 450 nm. The sample levels were calculated from the standard curve and corrected for protein concentration.

2.8. Statistics

The results are expressed as mean \pm SD. Data were analyzed by Graph Pad PRISM software. Differences among experimental groups




Fig. 1. Effect of adenosine kinase inhibitor (AKI, ABT-702) on retinal microglia activity (Iba-1 expression level) in TON. A) Immunoblotting analysis of microglial activation marker Iba-1 expression in TON vs. control in the retina, with and without AKI. B) Densitometry analysis of Iba1 and actin ratio by ImageJ software, NIH. C) RT-PCR analysis for Iba-1 mRNA level in retinal tissue. Data shown are the mean \pm SD (n = 4–6). *P < 0.05, **P < 0.01, and ***P < 0.001.




Fig. 2. Effect of adenosine kinase inhibitor (AKI, ABT-702) on ADK expression in the TON retinal tissue. A) Western blots analysis of ADK protein expression in retinal tissue in TON vs. control, with and without AKI treatment. B) Densitometry analysis was done for ADK and β-actin ratio by ImageJ software. C) Retinal ADK mRNA was determined by Real-Time PCR in TON vs. control, with and without AKI effect. Data shown are the mean \pm SD (n = 4). *P < 0.05, **P < 0.01, and ***P < 0.001.

were evaluated by analysis of variance (one-way ANOVA), and the significance of differences between groups was assessed by the posthoc test (Newman–Keuls multiple comparison). Significance was defined as $P < 0.05$.

3. Results

3.1. TON-induced microglial activation and its attenuation by adenosine kinase inhibitor

We have previously reported that TON activates microglia which leads to increased neurotoxicity and inflammation in retina and endogenous adenosine plays anti-inflammatory role by activating its receptor A_2AAR which further activates cAMP and inhibits MAPKinase pathway

(Ahmad et al., 2013). Here we showed that inhibiting adenosine kinase significantly reduced the hyper-activation of microglia. Western blot data showed that treatment with AKI (ABT-702) significantly reduced the Iba1 protein and mRNA expression in TON (Fig. 1A–C) ($p < 0.05$ and $p < 0.01$). In our earlier study, we observed that when microglia encountered TON milieu, they became activated as indicated by increased Iba-1 expression and lead to the Retinal Ganglion Cell death (Ahmad et al., 2013).

3.2. Role of AKI in retinal Adenosine kinase expression level in TON

We determined the effect of optic nerve crush on the expression of adenosine kinase in the retina. Our group has reported recently that adenosine kinase upregulated in retinal tissue of diabetic retinopathy (Elsherbiny et al., 2013). Adenosine kinase (ADK) converts endogenous adenosine into AMP. During stress condition exogenous adenosine is required in more quantity to work with its receptor but it seems that adenosine kinase plays negative role in traumatic condition by converting adenosine into AMP. Here, compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of ADK protein and mRNA expression. The treatment with AKI resulted in a marked reduction of TON-associated ADK protein and mRNA up-regulation (Fig. 2A–C). These results demonstrated that under TON-associated stress, ADK expression increased which means




Fig. 3. Role of AKI treatment on the retinal ENT1 expression level in the mouse model of TON. A) Analyses of ENT1 protein expression in TON model with and without AKI treatment by western blot. B) Densitometry analysis was done for ENT1 and β -actin ratio by Image J software (NIH). C) Retinal ENT1 mRNA was determined by Real-Time PCR in TON vs. control, with and without AKI effect. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.




Fig. 4. Effect of AKI treatment on pro-inflammatory cytokines expression in TON retinal tissue. A) and B) Real-Time PCR analysis of TNF- α and IL-6 mRNA expression in the retina of TON, with and without ABT-702 treatment. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

less adenosine availability outside but ADK inhibition may reverse this process.

3.3. Role of AKI in retinal Equilibrative nucleoside transporter-1 (ENT1) expression in TON

We next determined the effect of optic nerve crush on the levels of ENT1 expression in the retina. ENT1 regulates adenosine transportation from inside to outside and vice versa. Compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of ENT1 protein and mRNA. ABT-702 treatment in the eyes with crushed optic nerves significantly reduced TON-associated ENT1 protein and mRNA expression ($p < 0.01$ & $p < 0.05$) (Fig. 3A–C) ($n = 4$ –6).

3.4. Role of inflammation and its attenuation by AKI in TON mice

As shown in Fig. 7A and B, RT-PCR analysis of mRNA expression of TNF- α and IL-6 in the retinas of TON were notably increased as compared with TON contralateral eye. These cytokines were over produced by the hyper activation of microglia during traumatic condition (Ahmad et al., 2013). AKI treatment significantly reduced mRNA expression of TNF- α and IL-6 in the retinas of TON mice (Fig. 4A, B) ($p < 0.05$ and $p < 0.01$) ($n = 4$ –6).

3.5. Effect of AKI in retinal iNOS/nNOS expression

Furthermore, we examined the effect of AKI on retinal inducible and neuronal nitric oxide (iNOS/nNOS) expression level. iNOS is inducible only in pathological condition by inflammation or cytokines. After iNOS is induced, it is expected to produce large amount of nitric oxide (NO), which leads to RGS death during retinal traumatic condition. Similarly, overproduction of NO by nNOS has been reported in acute and chronic neurodegeneration. Here we found increased iNOS protein and mRNA expression in TON eye as compared with control. nNOS protein expression was also elevated in TON. Treatment with AKI significantly attenuated iNOS and nNOS protein and mRNA expression level when compared with TON ($p < 0.001$, $p < 0.05$ and $p < 0.01$) (Fig. 5A–E).

3.6. Effect of AKI in retinal oxidative stress

Since we found that iNOS/nNOS expression are upregulated in TON, we determined the effect of optic nerve crush on the levels of oxidative stress in the retina by two methods (DHE and nitrotyrosine staining) that measure superoxide generation and Nitrogen Reactive Species (NRS). Compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of superoxide determined by DHE and nitrotyrosine expression in eye section.




Fig. 5. Effect of AKI treatment on the retinal levels of iNOS/nNOS in the mouse model of TON. A) and B) Retinal iNOS protein expression was determined by western blotting in TON vs. control with and without AKI. Densitometry analysis of iNOS and β -actin band ratio was done by Image J software, NIH. C) RT-PCR analysis was done for iNOS mRNA expression in TON vs. TON + AKI group. D) and E) Retinal nNOS protein expression was determined by western blotting in TON vs. control with and without AKI. Densitometry analysis of nNOS and β -actin band ratio was done by Image J software, NIH. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

The AKI treatment resulted in a marked reduction of TON-associated superoxide production and nitrotyrosine expression compared with TON (Fig. 6A–D) ($p < 0.01$ & $p < 0.05$) ($n = 4–6$).

3.7. AKI treatment attenuates LPS- induced TNF- α release in mouse retinal microglia cells

We found that TON mice exhibit retinal inflammation. We next sought to explore a potential mechanism by which ADK signaling regulates inflammation in TON. To explore this, additional studies using mouse microglia cells treated with LPS were performed. Microglia with LPS or AGS treatment has been shown to simulate inflammation (Ibrahim et al., 2011; Elsherbiny et al., 2013). As shown in Fig. 7C, the treatment of retinal microglia cells with LPS triggered a prominent increase in TNF- α release. AKI treatment significantly reversed this process as compared with LPS induced cells ($p < 0.01$). p-P38 and p-ERK1/2 inhibitor were used to compare AKI effect and there were no significant changes.

3.8. Adenosine kinase signaling mediates the anti-inflammatory effect via interaction with LPS-activated MAPK pathway in mouse microglia cells

Here we studied the role of AKI on MAPKinase pathway and we checked the p-P38 and p-ERK1/2 activation in the LPS-induced microglia cells. Western blot analysis showed that LPS significantly activated MAPKinase signaling and inhibition of ADK by ABT-702 reduced its effect. These results demonstrated that adenosine kinase inhibition control the adenosine accumulation outside, and during traumatic

and stress condition adenosine activates one of its receptor A_{2A} ARs to block the MAPKinase activation which further inhibits activation of microglia. To prove this, we performed the immunofluorescence experiment that shows LPS treatment stimulated microglia (Iba-1) and p-ERK1/2 activation. Fig. 7D shows the co-localization of microglia marker Iba-1 (red) and p-ERK1/2 (green) with nucleus staining DAPI. Treatment with AKI inhibited the MAPKinase and microglia activation as compared with LPS treated cell.

4. Discussion

Inflammation plays a key role in many CNS diseases, including neural injury, infections and other diseases (Zheng et al., 2012). In case of optic nerve injury, inflammatory responses are immediately activated followed by activation of glial cells along with release of inflammatory molecules. In TON, influx of activated microglia play key role in retinal damage by secreting pro-inflammatory cytokines and cytotoxic molecules in response to oxidative stress. We previously demonstrated that extracellular adenosine has an anti-inflammatory effect in the retinal microglial cells near RGC mediated by adenosine receptor A_{2A} (A_{2A} AR) signaling (Ibrahim et al., 2011). Therapeutically, adenosine and its agonists have protective effect in various animal models of inflammation, hypoxia and ischemia but are limited there by systemic side effects such as hypotension, bradycardia, and sedation (Williams, 1996). In addition, physiological or inflammatory conditions limits adenosine availability because of its rapid reuptake via nucleoside transporters (NTs) and subsequently metabolized intracellularly (Moser et al., 1989).




Fig. 6. Effect of adenosine kinase inhibition by AKI on superoxide production and nitrotyrosine expression. A) and B) Dihydroethidium (DHE) staining was performed in frozen retinal section in TON vs. TON + AKI group. Color intensity was calculated by Image J Software. C, D) Immunofluorescence analysis of nitrotyrosine was done in the frozen retinal sections, TON vs. TON + AKI. Sections were stained with nitrotyrosine antibody with Alexa flour 488 (green) and DAPI (blue). Color intensity was measured by Image J Software. Data shown are the mean \pm SD ($n = 4–6$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

Adenosine kinase (ADK) is thought to be the principal enzyme responsible for regulating the level of adenosine under physiological conditions. Thus, use of ADK inhibitors represents an effective alternative for greater therapeutic effects of extracellular adenosine at particular site and event along with lower hemodynamic toxicity. Pharmacologic inhibition of ADK has been reported to exert beneficial effects in different disease models (Ugarkar et al., 2000; Vljakovic et al., 2011; Annes et al., 2012). In our earlier study, we also

demonstrated that ABT-702, a selective ADK inhibitor had a protective role in diabetic retina due to its potential to amplify therapeutic effects at site of injury (Elsherbiny et al., 2013).

The activation of microglia plays an important role in inflammatory response in TON (Zheng et al., 2012). We previously reported that TON milieu caused microglia activation as indicated by increased Iba-1 expression (Ahmad et al., 2013). In the present study, ABT-702 treatment inhibited TON- induced increase of retinal Iba-1 levels. Further,





Fig. 7. Role of MAPKinase in the ADK-mediated anti-inflammation: LPS-induced TNF-α release in the mouse microglia cells and its attenuation with AKI. A) LPS induced activation of ERK in the mouse microglia cells. Phosphorylated (p) ERK and its total protein were determined by western blot analysis in control, LPS and LPS+AKI cell lysates. B) Phosphorylated P38 and its total protein were determined by western blot analysis in control, LPS and LPS+AKI cell lysates. C) TNF-α release was measured by ELISA in LPS induced mouse microglia cells in control, LPS and LPS+AKI cell lysates supernatants. D) Immunofluorescence analysis of Iba-1 and pERK1/2 expression level in microglia cells. LPS activates Iba-1 and pERK1/2 as compared with control, and AKI treatment inhibited their activation in LPS treatment. Iba-1 and pERK1/2 were stained with Alexa fluor 594 (red) and Alexa fluor 488 (green) respectively and DAPI (blue) for nucleus. U0126 (MEK inhibitor) and SB203580 (P38 inhibitor) were used to compare AKI. Data shown are the mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001.

Further, we investigated the effect of ABT-702 treatment on TON induced oxidative stress. We previously demonstrated increased oxidative stress in mice retina with TON (Ahmad et al., 2013). Here, we studied the effect of ABT-702 treatment on superoxide anion, iNOS/nNOS and nitrotyrosine levels in mice retina with TON. Nitration of tyrosine residues is evident in several retinal inflammatory and neurodegenerative diseases (Gouder et al., 2004), which occurs due to reaction of tyrosine with reactive nitrogen species such as peroxynitrite (Pacher et al., 2007). These reactive nitrogen species are formed by reaction of superoxide anion and Nitric oxide (NO), thus, serving as a likely indicator simultaneous generation of NO and superoxide (El-Remessy et al., 2003). However, It is reported that retinal ganglion cell loss during retinal hypoxia regulated by NO (Kaur et al., 2006). Under pathological conditions, NO is synthesized by the inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS). Studies reported the expression of nNOS and iNOS in glial cells, infiltrating leukocytes and in RGCs in hypoxic retina (Kashiwagi et al., 2003; Kaur et al., 2006). The produced NO from nNOS and iNOS contributes to neurotoxicity resulting in cell death and axonal damage (Kaur et al., 2008). Report suggests that NO triggered several pathways including N-methyl-D-aspartate (NMDA)-mediated intracellular Ca^{2+} influx and CREB-mediated apoptotic proteins which results to neuronal death (Mishra et al., 2002). Increased NO production is shown to mediate MAPKinase activation during hypoxia in cerebral cortical nuclei of




In conclusion we may demonstrate that inhibition of adenosine kinase attenuates TON induced inflammation and neurotoxicity by stimulating adenosine signaling and inhibiting MAPKinase pathway in activated retinal microglia cells (Fig. 8).

Ahmad, S., Fatteh, N., El-Sherbiny, N.M., Naime, M., Ibrahim, A.S., El-Sherbini, A.M., El-Shafey, S.A., Khan, S., Fulzele, S., Gonzales, J., Liou, G.I., 2013. **Potential role of A2A adenosine receptor in traumatic optic neuropathy.** *J. Neuroimmunol.* 264, 54–64.

Ajizian, S.J., English, B.K., Meals, E.A., 1999. **Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible**

- nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. *J. Infect. Dis.* 179, 939–944.
- Annes, J.P., Ryu, J.H., Lam, K., Carolan, P.J., Utz, K., Hollister-Lock, J., Arvanites, A.C., Rubin, L.L., Weir, G., Melton, D.A., 2012. Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication. *Proc. Natl. Acad. Sci. U. S. A.* 109, 3915–3920.
- Boison, D., 2008. Adenosine as a neuromodulator in neurological diseases. *Curr. Opin. Pharmacol.* 8, 2–7.
- Boison, D., Shen, H.Y., 2010. Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. *Open Drug Discov. J.* 2, 108–118.
- El-Remessy, A.B., Abou-Mohamed, G., Caldwell, R.W., Caldwell, R.B., 2003. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. *Invest. Ophthalmol. Vis. Sci.* 44, 3135–3143.
- Elsherbiny, N.M., Ahmad, S., Naime, M., Elsherbiny, A.M., Fulzele, S., Al-Gayyar, M.M., Eissa, L.A., El-Shishtawy, M.M., Liou, G.I., 2013. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. *Life Sci.* 93, 78–88.
- Fredholm, B.B., Chen, J.F., Cunha, R.A., Svenningsson, P., Vaugeois, J.M., 2005. Adenosine and brain function. *Int. Rev. Neurobiol.* 63, 191–270.
- Gouder, N., Scheurer, L., Fritschy, J.M., Boison, D., 2004. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. *J. Neurosci.* 24, 692–701.
- Hagberg, H., Andersson, P., Lacarewicz, J., Jacobson, I., Butcher, S., Sandberg, M., 1987. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. *J. Neurochem.* 49, 227–231.
- Ibrahim, A.S., El-Shishtawy, M.M., Zhang, W., Caldwell, R.B., Liou, G.I., 2011. A(2)A adenosine receptor (A(2)A)AR as a therapeutic target in diabetic retinopathy. *Am. J. Pathol.* 178, 2136–2145.
- Kashiwagi, K., Iizuka, Y., Mochizuki, S., Tsumamoto, Y., Mishima, H.K., Araie, M., Suzuki, Y., Tsukahara, S., 2003. Differences in nitric oxide production: a comparison of retinal ganglion cells and retinal glial cells cultured under hypoxic conditions. *Brain Res. Mol. Brain Res.* 112, 126–134.
- Kaur, C., Sivakumar, V., Foulds, W.S., 2006. Early response of neurons and glial cells to hypoxia in the retina. *Invest. Ophthalmol. Vis. Sci.* 47, 1126–1141.
- Kaur, C., Foulds, W.S., Ling, E.A., 2008. Hypoxia–ischemia and retinal ganglion cell damage. *Clin. Ophthalmol.* 2, 879–889.
- Leung, G.P., Man, R.Y., Tse, C.M., 2005. D-Glucose upregulates adenosine transport in cultured human aortic smooth muscle cells. *Am. J. Physiol. Heart Circ. Physiol.* 288, H2756–H2762.
- Liou, G.I., 2010. Diabetic retinopathy: role of inflammation and potential therapies for anti-inflammation. *World J. Diabetes* 1, 12–18.
- Lucas, S.M., Rothwell, N.J., Gibson, R.M., 2006. The role of inflammation in CNS injury and disease. *Br. J. Pharmacol.* 147 (Suppl. 1), S232–S240.
- Lusardi, T.A., 2009. Adenosine neuromodulation and traumatic brain injury. *Curr. Neuropharmacol.* 7, 228–237.
- Meno, J.R., Ngai, A.C., Ibayashi, S., Winn, H.R., 1991. Adenosine release and changes in pial arteriolar diameter during transient cerebral ischemia and reperfusion. *J. Cereb. Blood Flow Metab.* 11, 986–993.
- Mishra, O.P., Ashraf, Q.M., Delivoria-Papadopoulos, M., 2002. Phosphorylation of cAMP response element binding (CREB) protein during hypoxia in cerebral cortex of newborn piglets and the effect of nitric oxide synthase inhibition. *Neuroscience* 115, 985–991.
- Mishra, O.P., Zubrow, A.B., Ashraf, Q.M., 2004. Nitric oxide-mediated activation of extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) during hypoxia in cerebral cortical nuclei of newborn piglets. *Neuroscience* 123, 179–186.
- Moser, G.H., Schrader, J., Deussen, A., 1989. Turnover of adenosine in plasma of human and dog blood. *Am. J. Physiol.* 256, C799–C806.
- Pacher, P., Beckman, J.S., Liaudet, L., 2007. Nitric oxide and peroxynitrite in health and disease. *Physiol. Rev.* 87, 315–424.
- Pang, T., Gan, X.T., Freeman, D.J., Cook, M.A., Karmazyn, M., 2010. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. *Am. J. Physiol. Heart Circ. Physiol.* 298, H545–H553.
- Phillis, J.W., Walter, G.A., Simpson, R.E., 1991. Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycytidine. *J. Neurochem.* 56, 644–650.
- Shen, H.Y., Singer, P., Lytle, N., Wei, C.J., Lan, J.Q., Williams-Karnesky, R.L., Chen, J.F., Yee, B.K., Boison, D., 2012. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. *J. Clin. Invest.* 122, 2567–2577.
- Smith, J.A., Das, A., Ray, S.K., Banik, N.L., 2012. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res. Bull.* 87, 10–20.
- Steinsapir, K.D., Goldberg, R.A., 2011. Traumatic optic neuropathy: an evolving understanding. *Am. J. Ophthalmol.* 151 (928–933), e922.
- Tatlisumak, T., Takano, K., Carano, R.A., Miller, L.P., Foster, A.C., Fisher, M., 1998. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. *Stroke* 29, 1952–1958.
- Ugarkar, B.G., Castellino, A.J., DaRe, J.M., Kopcho, J.J., Wiesner, J.B., Schanzer, J.M., Erion, M.D., 2000. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. *J. Med. Chem.* 43, 2894–2905.
- Vlajkovic, S.M., Guo, C.X., Telang, R., Wong, A.C., Paramanathasivam, V., Boison, D., Housley, G.D., Thorne, P.R., 2011. Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss. *Exp. Gerontol.* 46, 905–914.
- White, T.D., 1996. Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. *Eur. J. Pharmacol.* 303, 27–38.
- Williams, M., 1996. Challenges in developing P2 purinoceptor-based therapeutics. *Ciba Found. Symp.* 198, 309–321.
- Zheng, Z., Yuan, R., Song, M., Huo, Y., Liu, W., Cai, X., Zou, H., Chen, C., Ye, J., 2012. The toll-like receptor 4-mediated signaling pathway is activated following optic nerve injury in mice. *Brain Res.* 1489, 90–97.



Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy

Saif Ahmad^{a,b,*}, Nehal M. Elsherbiny^{a,c}, Kanchan Bhatia^b, Ahmed M. Elsherbini^a,
Sadanand Fulzele^d, Gregory I. Liou^{a,**}

^a Department of Ophthalmology, School of Medicine, Georgia Regents University (GRU), Augusta, GA, USA

^b Department of Biological Sciences, Rabigh College of Science and Arts, King Abdulaziz University, Rabigh, Saudi Arabia

^c Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

^d Department of Orthopedics, Georgia Regents University (GRU), Augusta, GA, USA

ARTICLE INFO

Article history:

Received 17 June 2014

Received in revised form 3 October 2014

Accepted 15 October 2014

Keywords:

Traumatic optic neuropathy

Adenosine kinase

ABT-702

Microglia

Inflammation

MAPKinase

ABSTRACT

Traumatic optic neuropathy (TON) is associated with apoptosis of retinal ganglion cells. Local productions of reactive oxygen species and inflammatory mediators from activated microglial cells have been hypothesized to underlie apoptotic processes. We previously demonstrated that the anti-inflammatory effect of adenosine, through A_{2A} receptor activation had profound protective influence against retinal injury in traumatic optic neuropathy. This protective effect is limited due to rapid cellular re-uptake of adenosine by equilibrative nucleoside transporter-1 (ENT1) or break down by adenosine kinase (AK), the key enzyme in adenosine clearance pathway. Further, the use of adenosine receptors agonists are limited by systemic side effects. Therefore, we seek to investigate the potential role of amplifying the endogenous ambient level of adenosine by pharmacological inhibition of AK. We tested our hypothesis by comparing TON-induced retinal injury in mice with and without ABT-702 treatment, a selective AK inhibitor (AKI). The retinal-protective effect of ABT-702 was demonstrated by significant reduction of Iba-1, ENT1, TNF- α , IL-6, and iNOS/nNOS protein or mRNA expression in TON as revealed by western blot and real time PCR. TON-induced superoxide anion generation and nitrotyrosine expression were reduced in ABT-702 treated mice retinal sections as determined by immunofluorescence. In addition, ABT-702 attenuated p-ERK1/2 and p-P38 activation in LPS induced activated mouse microglia cells. The results of the present investigation suggested that ABT-702 had a protective role against marked TON-induced retinal inflammation and damage by augmenting the endogenous therapeutic effects of site- and event-specific accumulation of extracellular adenosine.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Traumatic optic neuropathy (TON) is partial or complete loss of function of optic nerve (ON) due to either a direct injury or indirectly after head trauma sequelae, such as edema, hemorrhage, and concussion (Steinsapir and Goldberg, 2011). Unfortunately, there are currently no proven treatments that can prevent the damage associated with an acute TON. Optic nerve injury mediated loss of retinal ganglion cells (RGCs) through apoptosis has been hypothesized due to several

underlying common mechanisms, including lack of neurotrophin support, increased extracellular glutamate levels, damage from free radicals, and disruption of cellular homeostasis (Pang et al., 2010). All these mechanisms cause activation of microglial cells and inflammatory responses such as release of free radicals, cytokines, and prostaglandins and complement molecules (Lucas et al., 2006). Therefore, counteracting inflammation may possess neuroprotective effect in TON.

Adenosine is a ubiquitous homeostatic purine nucleoside that accumulates extracellularly in response to metabolic stresses such as hypoxia and inflammation. Activation of either G protein-coupled adenosine receptors (ARs; A₁R, A_{2A}R, A_{2B}R, and A₃R) by extracellular adenosine can modulate cell signaling. However, A_{2A} receptor activation significantly modulates neuronal integrity and neuroprotection by adenosine receptor modulation has been demonstrated in several model systems (Lusardi, 2009). In accordance, we have demonstrated that A_{2A}AR signaling had a protective effect in traumatic optic neuropathy by attenuating microglia induced inflammatory response (Ahmad et al., 2013).

ARs agonists have limited therapeutic use due to systemic side effects (Fredholm et al., 2005). However, a promising alternative might

Abbreviations: TON, traumatic optic neuropathy; TNF- α , tumor necrosis factor- α ; ELISA, enzyme-linked immunosorbent assay; ROS, reactive oxygen species; MAP kinase, mitogen-activated protein kinase; ERK, P38, extracellular signal-regulated kinase; AR, adenosine receptor; AKI, adenosine kinase inhibitor; ABT-702, 2-p-[2-Carboxyethyl]phenethylamino-5'-N-ethylcarboxamidoadenosine; LPS, lipopolysaccharides.

* Correspondence to: S. Ahmad, Department of Biological Sciences, Rabigh College of Science and Arts, King Abdulaziz University, Post Box 344, Rabigh-21911, Saudi Arabia. Tel.: +966 594355530.

** Correspondence to: G.I. Liou, Department of Ophthalmology, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA. Tel.: +1 706 721 4599; fax: +1 706 721 1158.

E-mail addresses: asaif77@yahoo.com (S. Ahmad), giliou@gru.edu (G.I. Liou).

be the augmentation of the adenosine levels by targeting enzymes or nucleoside transporters that regulate the extracellular levels of adenosine (Shen et al., 2012). Metabolic clearance of adenosine occurs through key enzyme adenosine kinase (ADK) and evidence shows that the inhibition of this enzyme increases extracellular adenosine levels in cell and tissues (Boison and Shen, 2010). Indeed, the inhibition of ADK has been proven to possess potential therapeutic usefulness in a wide range of neurological disorders (Boison, 2008). In this context, we previously reported that pharmacologic inhibition of ADK augments adenosine and exerts activity in retina of diabetic mice (Elsherbiny et al., 2013). Here, we seek to investigate the retinal protective role of ABT-702, a selective adenosine kinase inhibitor against marked TON-induced retinal inflammation and damage.

2. Materials and methods

2.1. Experimental design

All procedures with animals were performed in accordance with the Public Health Service Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and Welfare publication, NIH 80-23) and Georgia Regents University, Augusta, GA, USA guidelines. Eightto tenweek-old male wild-type (WT) mice (16 mice in each group) in C57BL/6 background were used for experiments. Mice were anesthetized according to standard protocol and limbal conjunctival peritomy was performed on one eye of each mouse. Forceps dissection under the conjunctiva posteriorly allowed access to the optic nerve, upon which pressure was placed 1 mm posterior to the globe until pupillary dilation was noted (approximately 10 s). Blood vessel close to optic nerve was carefully avoided in TON surgery. Mock-operated contra lateral eye served as the control. After one week, all mice were sacrificed. Eyes were enucleated and sectioned for histological analysis. Retinas were harvested for Western or Real Time PCR analysis. In pharmacologic studies, age-, weight- and sex-matched C57BL/6 mice were rendered optic nerve crush and then injected i.p. with vehicle (DMSO), or ABT-702 (AKI, Adenosine Kinase Inhibitor) (1.5 mg/kg bwt, i.p.) every other day for the duration of the study (n = 4–6/group).

2.2. Western blot analysis

Protein expression was measured by western blotting. In brief, washed cultured cells or retinal tissues were lysed in modified RIPA buffer (Upstate, Lake Placid, NY), containing 50 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic acid, 1% Nonidet P-40, 0.25% deoxycholate, supplemented with 40 mmol/L NaF, 2 mmol/L Na₃VO₄, 0.5 mmol/L phenylmethylsulfonyl fluoride and 1:100 (v/v) of proteinase inhibitor cocktail (Sigma). Insoluble material was removed by centrifugation at 12,000 × g at 4 °C for 30 min. Protein was determined by Bradford method (Bio-Rad, Hercules, CA). 50–100 µg was boiled in Laemmli sample buffer, separated by SDS-PAGE on a gradient gel (4 to 20%) (Pierce, Rockford, IL), transferred to nitrocellulose membrane and incubated with specific antibodies. Antibodies for β-actin (Sigma), Iba1 (Wako, Japan), ADK, iNOS, nNOS, nitrotyrosine and ENT1 from Santa cruz Biotechnology Inc., CA, and phospho-ERK and ERK (Cell Signaling Technology, Beverly, MA) were detected with a horseradish peroxidase-conjugated antibody and ECL chemiluminescence (Amersham BioSciences, Buckinghamshire, UK). Intensity of immunoreactivity was measured by densitometry.

2.3. Immunohistochemical analysis

Immunofluorescence analysis was performed using frozen retinal sections. Briefly, cryostat sections (10 µm) were fixed in 4% paraformaldehyde, blocked with 10% normal goat serum (NGS) and then incubated overnight at 4 °C with primary antibodies: Rabbit anti-nitrotyrosine, rabbit anti-Iba-1 (Wako Pure Chemical, Wako, TX), or mouse anti-

pERK1/2 antibody (Cell signaling technology, USA). Thereafter, sections were briefly washed with 1X PBS-T (0.1%) or 0.3% Triton X-100 and incubated with appropriate secondary antibodies (Invitrogen). Slides were examined under the fluorescence microscope (Carl Zeiss). Specificity of the reaction was confirmed by omitting the primary antibody. Data (10 fields/retina, n = 4–6 in each group) were analyzed using fluorescence microscopy and Ultra-View morphometric software or Image J software (NIH) to quantify the intensity of immunostaining.

2.4. Real-time PCR (isolation of RNA, synthesis of cDNA)

Total RNA was isolated from mouse retina using SV Total RNA Isolation kit (Promega, Madison, WI) following manufacturer's instructions, and the quality of the RNA preparations was monitored by absorbance at 260 and 280 nm (Helios-Gamma, Thermo Spectronic, Rochester, NY). The RNA was reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using iScript reagents from Bio-Rad in a programmable thermal cycler (PCR-Sprint, Thermo Electron, Milford, MA). 50 ng of cDNA was amplified in each real-time PCR using Bio-Rad iCycler, ABgene reagents (Fisher scientific) and appropriate primers (Table 1). An average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA was used as the internal control for normalization.

2.5. Analysis of dihydroethidium (DHE) fluorescence for the detection of superoxide

The detection of superoxide anion in the mouse eye sections was performed as described previously (Ahmad et al., 2013). In brief, mouse eyes were frozen in OCT and stored at −80 °C until use. Enzymatically intact eye sections were thawed in room temperature, rehydrated with PBS, incubated with dihydroethidium (DHE; 10 µMol/L in PBS) for 30 min at 37 °C in a humidified chamber protected from light. After incubation, sections were washed with PBS. DHE is oxidized on reaction with superoxide to ethidium, which binds to DNA in the nucleus and emits red fluorescence. For the detection of ethidium, samples were examined with a fluorescence microscope (Axioskop 2 plus with AxioCam; Carl Zeiss, Germany; Excitation/Emission wavelengths: 518/605 nm). DHE fluorescence was quantified using Image J software (NIH).

2.6. Mouse microglia cell culture, drugs treatment

The mouse microglial cell line EOC-20 was obtained from the American Type Culture Collection (ATCC CRL-2469, Manassas, VA, USA). Cells were maintained at 37 °C and 5% CO₂ in DMEM supplemented with 10% fetal bovine serum, 0.5% penicillin/streptomycin, 4 mM L-glutamine, and 20% conditioned medium from bone-marrow-derived Ladam cells (ATCC CRL-2420) as a source of colony stimulating

Table 1

The primer sets used for the detection of mouse genes by quantitative real-time PCR analysis.

Gene	Primer sequence (5'-3')	Accession number
TNF-α	CCCTCACACTCAGATCATCTTCT GTCACGACGTGGGCTACAG	NM_013693.2
ENT1	CAAGTATTTTCAAAACCGCTGGAC GAAACGAGTTGAGGCGAGTGAAGAC	Am J Physiol Heart Circ Physiol 299:H847–H856, 2010
Iba-1	GTCTTGAAGCGAATGCTGG CATTCTCAAGATGGCAGATC	NM_019467
iNOS	ACA TCG ACC CGT CCA CAG TAT CAG AGG GGT AGG CTT GTC TC	Primer Bank ID 6754872
IL-6	TAGTCCTTCTACCCCAATTTC TTGGTCCTTAGCCACTCCTTC	NM_031168.1
GAPDH	CAT GGC CTC CAA GGA GTAAGAGAG GGA GAT GCT CAG TGT TGG	M32599
18S	AGT GCG GGT CAT AAG CTT GC GGG CCT CAC TAA ACC ATC CA	NR_003278

factor-1. EOC-20 cells were grown to 60% confluence at which point their media were removed and replaced with fresh medium. Microglial cells were seeded in a 6-well tissue culture plate. One day after seeding, the wells were washed with DMEM and incubated in the same media with various treatments. Cells were pretreated with ABT-702 (AKI-20 μ M, Tocris, Ellisville, MO), SB203580 (P38 inhibitor, 20 μ M) and U0126 (MEK inhibitor, 20 μ M) at the indicated concentrations reported previously or vehicle dimethylsulfoxide (DMSO) for 30 min at 37 °C before LPS (50 ng/ml for 24 h) treatment. At indicated time points, cells were harvested and homogenized for Western blot analysis and culture media were taken and analyzed for TNF- α by ELISA. For immunocytochemistry, mouse microglia cells were grown in 4 well chambers and after the drug treatment and indicated time point cells were fixed in 4% paraformaldehyde for 20 min and then washed with PBS and the slides were stored at 4 °C for immunofluorescence study.

2.7. Enzyme-linked immunosorbent assay (ELISA) for TNF- α

TNF- α levels in the supernatants of culture media were estimated with ELISA kits (R&D, Minneapolis, MN) as per the manufacturer's instructions. Standards and samples were added and bound by the immobilized antibody. After washing, an enzyme-linked polyclonal antibody specific for the cytokine was added to the wells followed by a substrate solution yielding a colored product. The intensity of the color was measured at 450 nm. The sample levels were calculated from the standard curve and corrected for protein concentration.

2.8. Statistics

The results are expressed as mean \pm SD. Data were analyzed by Graph Pad PRISM software. Differences among experimental groups




Fig. 1. Effect of adenosine kinase inhibitor (AKI, ABT-702) on retinal microglia activity (Iba-1 expression level) in TON. A) Immunoblotting analysis of microglial activation marker Iba-1 expression in TON vs. control in the retina, with and without AKI. B) Densitometry analysis of Iba1 and actin ratio by Image J software, NIH. C) RT-PCR analysis for Iba-1 mRNA level in retinal tissue. Data shown are the mean \pm SD (n = 4–6). *P < 0.05, **P < 0.01, and ***P < 0.001.




Fig. 2. Effect of adenosine kinase inhibitor (AKI, ABT-702) on ADK expression in the TON retinal tissue. A) Western blots analysis of ADK protein expression in retinal tissue in TON vs. control, with and without AKI treatment. B) Densitometry analysis was done for ADK and β-actin ratio by Image J software. C) Retinal ADK mRNA was determined by Real-Time PCR in TON vs. control, with and without AKI effect. Data shown are the mean \pm SD (n = 4). *P < 0.05, **P < 0.01, and ***P < 0.001.

were evaluated by analysis of variance (one-way ANOVA), and the significance of differences between groups was assessed by the posthoc test (Newman–Keuls multiple comparison). Significance was defined as $P < 0.05$.

3. Results

3.1. TON-induced microglial activation and its attenuation by adenosine kinase inhibitor

We have previously reported that TON activates microglia which leads to increased neurotoxicity and inflammation in retina and endogenous adenosine plays anti-inflammatory role by activating its receptor A_2AAR which further activates cAMP and inhibits MAPKinase pathway

(Ahmad et al., 2013). Here we showed that inhibiting adenosine kinase significantly reduced the hyper-activation of microglia. Western blot data showed that treatment with AKI (ABT-702) significantly reduced the Iba1 protein and mRNA expression in TON (Fig. 1A–C) ($p < 0.05$ and $p < 0.01$). In our earlier study, we observed that when microglia encountered TON milieu, they became activated as indicated by increased Iba-1 expression and lead to the Retinal Ganglion Cell death (Ahmad et al., 2013).

3.2. Role of AKI in retinal Adenosine kinase expression level in TON

We determined the effect of optic nerve crush on the expression of adenosine kinase in the retina. Our group has reported recently that adenosine kinase upregulated in retinal tissue of diabetic retinopathy (Elsherbiny et al., 2013). Adenosine kinase (ADK) converts endogenous adenosine into AMP. During stress condition exogenous adenosine is required in more quantity to work with its receptor but it seems that adenosine kinase plays negative role in traumatic condition by converting adenosine into AMP. Here, compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of ADK protein and mRNA expression. The treatment with AKI resulted in a marked reduction of TON-associated ADK protein and mRNA up-regulation (Fig. 2A–C). These results demonstrated that under TON-associated stress, ADK expression increased which means




Fig. 3. Role of AKI treatment on the retinal ENT1 expression level in the mouse model of TON. A) Analyses of ENT1 protein expression in TON model with and without AKI treatment by western blot. B) Densitometry analysis was done for ENT1 and β -actin ratio by Image J software (NIH). C) Retinal ENT1 mRNA was determined by Real-Time PCR in TON vs. control, with and without AKI effect. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.




Fig. 4. Effect of AKI treatment on pro-inflammatory cytokines expression in TON retinal tissue. A) and B) Real-Time PCR analysis of TNF- α and IL-6 mRNA expression in the retina of TON, with and without ABT-702 treatment. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

less adenosine availability outside but ADK inhibition may reverse this process.

3.3. Role of AKI in retinal Equilibrative nucleoside transporter-1 (ENT1) expression in TON

We next determined the effect of optic nerve crush on the levels of ENT1 expression in the retina. ENT1 regulates adenosine transportation from inside to outside and vice versa. Compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of ENT1 protein and mRNA. ABT-702 treatment in the eyes with crushed optic nerves significantly reduced TON-associated ENT1 protein and mRNA expression ($p < 0.01$ & $p < 0.05$) (Fig. 3A–C) ($n = 4$ –6).

3.4. Role of inflammation and its attenuation by AKI in TON mice

As shown in Fig. 7A and B, RT-PCR analysis of mRNA expression of TNF- α and IL-6 in the retinas of TON were notably increased as compared with TON contralateral eye. These cytokines were over produced by the hyper activation of microglia during traumatic condition (Ahmad et al., 2013). AKI treatment significantly reduced mRNA expression of TNF- α and IL-6 in the retinas of TON mice (Fig. 4A, B) ($p < 0.05$ and $p < 0.01$) ($n = 4$ –6).

3.5. Effect of AKI in retinal iNOS/nNOS expression

Furthermore, we examined the effect of AKI on retinal inducible and neuronal nitric oxide (iNOS/nNOS) expression level. iNOS is inducible only in pathological condition by inflammation or cytokines. After iNOS is induced, it is expected to produce large amount of nitric oxide (NO), which leads to RGS death during retinal traumatic condition. Similarly, overproduction of NO by nNOS has been reported in acute and chronic neurodegeneration. Here we found increased iNOS protein and mRNA expression in TON eye as compared with control. nNOS protein expression was also elevated in TON. Treatment with AKI significantly attenuated iNOS and nNOS protein and mRNA expression level when compared with TON ($p < 0.001$, $p < 0.05$ and $p < 0.01$) (Fig. 5A–E).

3.6. Effect of AKI in retinal oxidative stress

Since we found that iNOS/nNOS expression are upregulated in TON, we determined the effect of optic nerve crush on the levels of oxidative stress in the retina by two methods (DHE and nitrotyrosine staining) that measure superoxide generation and Nitrogen Reactive Species (NRS). Compared with the contralateral eyes, the eyes with crushed optic nerves demonstrated a significant increase in the levels of superoxide determined by DHE and nitrotyrosine expression in eye section.




Fig. 5. Effect of AKI treatment on the retinal levels of iNOS/nNOS in the mouse model of TON. A) and B) Retinal iNOS protein expression was determined by western blotting in TON vs. control with and without AKI. Densitometry analysis of iNOS and β -actin band ratio was done by Image J software, NIH. C) RT-PCR analysis was done for iNOS mRNA expression in TON vs. TON + AKI group. D) and E) Retinal nNOS protein expression was determined by western blotting in TON vs. control with and without AKI. Densitometry analysis of nNOS and β -actin band ratio was done by Image J software, NIH. Data shown are the mean \pm SD ($n = 4$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

The AKI treatment resulted in a marked reduction of TON-associated superoxide production and nitrotyrosine expression compared with TON (Fig. 6A–D) ($p < 0.01$ & $p < 0.05$) ($n = 4–6$).

3.7. AKI treatment attenuates LPS- induced TNF- α release in mouse retinal microglia cells

We found that TON mice exhibit retinal inflammation. We next sought to explore a potential mechanism by which ADK signaling regulates inflammation in TON. To explore this, additional studies using mouse microglia cells treated with LPS were performed. Microglia with LPS or AGS treatment has been shown to simulate inflammation (Ibrahim et al., 2011; Elsherbiny et al., 2013). As shown in Fig. 7C, the treatment of retinal microglia cells with LPS triggered a prominent increase in TNF- α release. AKI treatment significantly reversed this process as compared with LPS induced cells ($p < 0.01$). p-P38 and p-ERK1/2 inhibitor were used to compare AKI effect and there were no significant changes.

3.8. Adenosine kinase signaling mediates the anti-inflammatory effect via interaction with LPS-activated MAPK pathway in mouse microglia cells

Here we studied the role of AKI on MAPKinase pathway and we checked the p-P38 and p-ERK1/2 activation in the LPS-induced microglia cells. Western blot analysis showed that LPS significantly activated MAPKinase signaling and inhibition of ADK by ABT-702 reduced its effect. These results demonstrated that adenosine kinase inhibition control the adenosine accumulation outside, and during traumatic

and stress condition adenosine activates one of its receptor A_{2A} ARs to block the MAPKinase activation which further inhibits activation of microglia. To prove this, we performed the immunofluorescence experiment that shows LPS treatment stimulated microglia (Iba-1) and p-ERK1/2 activation. Fig. 7D shows the co-localization of microglia marker Iba-1 (red) and p-ERK1/2 (green) with nucleus staining DAPI. Treatment with AKI inhibited the MAPKinase and microglia activation as compared with LPS treated cell.

4. Discussion

Inflammation plays a key role in many CNS diseases, including neural injury, infections and other diseases (Zheng et al., 2012). In case of optic nerve injury, inflammatory responses are immediately activated followed by activation of glial cells along with release of inflammatory molecules. In TON, influx of activated microglia play key role in retinal damage by secreting pro-inflammatory cytokines and cytotoxic molecules in response to oxidative stress. We previously demonstrated that extracellular adenosine has an anti-inflammatory effect in the retinal microglial cells near RGC mediated by adenosine receptor A_{2A} (A_{2A} AR) signaling (Ibrahim et al., 2011). Therapeutically, adenosine and its agonists have protective effect in various animal models of inflammation, hypoxia and ischemia but are limited there by systemic side effects such as hypotension, bradycardia, and sedation (Williams, 1996). In addition, physiological or inflammatory conditions limits adenosine availability because of its rapid reuptake via nucleoside transporters (NTs) and subsequently metabolized intracellularly (Moser et al., 1989).




Fig. 6. Effect of adenosine kinase inhibition by AKI on superoxide production and nitrotyrosine expression. A) and B) Dihydroethidium (DHE) staining was performed in frozen retinal section in TON vs. TON + AKI group. Color intensity was calculated by Image J Software. C, D) Immunofluorescence analysis of nitrotyrosine was done in the frozen retinal sections, TON vs. TON + AKI. Sections were stained with nitrotyrosine antibody with Alexa flour 488 (green) and DAPI (blue). Color intensity was measured by Image J Software. Data shown are the mean \pm SD ($n = 4–6$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

Adenosine kinase (ADK) is thought to be the principal enzyme responsible for regulating the level of adenosine under physiological conditions. Thus, use of ADK inhibitors represents an effective alternative for greater therapeutic effects of extracellular adenosine at particular site and event along with lower hemodynamic toxicity. Pharmacologic inhibition of ADK has been reported to exert beneficial effects in different disease models (Ugarkar et al., 2000; Vljakovic et al., 2011; Annes et al., 2012). In our earlier study, we also

demonstrated that ABT-702, a selective ADK inhibitor had a protective role in diabetic retina due to its potential to amplify therapeutic effects at site of injury (Elsherbiny et al., 2013).

The activation of microglia plays an important role in inflammatory response in TON (Zheng et al., 2012). We previously reported that TON milieu caused microglia activation as indicated by increased Iba-1 expression (Ahmad et al., 2013). In the present study, ABT-702 treatment inhibited TON- induced increase of retinal Iba-1 levels. Further,




Fig. 7. Role of MAPKinase in the ADK-mediated anti-inflammation: LPS-induced TNF-α release in the mouse microglia cells and its attenuation with AKI. A) LPS induced activation of ERK in the mouse microglia cells. Phosphorylated (p) ERK and its total protein were determined by western blot analysis in control, LPS and LPS+AKI cell lysates. B) Phosphorylated P38 and its total protein were determined by western blot analysis in control, LPS and LPS+AKI cell lysates. C) TNF-α release was measured by ELISA in LPS induced mouse microglia cells in control, LPS and LPS+AKI cell lysates supernatants. D) Immunofluorescence analysis of Iba-1 and pERK1/2 expression level in microglia cells. LPS activates Iba-1 and pERK1/2 as compared with control, and AKI treatment inhibited their activation in LPS treatment. Iba-1 and pERK1/2 were stained with Alexa fluor 594 (red) and Alexa fluor 488 (green) respectively and DAPI (blue) for nucleus. U0126 (MEK inhibitor) and SB203580 (P38 inhibitor) were used to compare AKI. Data shown are the mean ± SD (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001.

activated microglia released inflammatory molecules such as IL-6, and TNF- α , which may be toxic to neurons and other glial cells (Smith et al., 2012). Here, we found that ABT-702 reduced retinal increase of mRNA levels of TNF- α and IL-6 in TON. These findings suggest that ABT-702 exerted its protective effect by augmenting the anti-inflammatory mechanism of adenosine mediated by attenuation of microglia activation.

Furthermore, we found up-regulated protein and mRNA levels of adenosine kinase in mouse retina with TON. The up-regulation of ADK was previously demonstrated in diabetic retinopathy (Pang et al., 2010). Greater levels of ADK in activated macrophages and microglial cells abrogate the immune response. Earlier research showed that adenosine level dramatically increase in extracellular in ischemic condition (Hagberg et al., 1987), and also in the rat model of transient ischemia the concentration of adenosine in the cerebrospinal fluid was increased four-fold (Meno et al., 1991). Previous reports have shown that a beneficial role of elevated adenosine in ischemic condition, and the increased adenosine accumulation appears to be protective in brain cell injury (Phillis et al., 1991; Tatlisumak et al., 1998). However, adenosine kinase influences adenosine reuptake by converting into AMP. During ischemic or traumatic condition cells need more adenosine but other side adenosine kinase inhibits adenosine production. In current study ABT-702 significantly reduced the adenosine kinase protein and mRNA expression. Thus, the inhibition of adenosine kinase seems beneficial for the adenosine signaling. Our results are in agreement with others where adenosine kinase inhibition with selective ADK inhibitors showed increased adenosine level in brain cells and retinal inflammation (White, 1996; Tatlisumak et al., 1998; Elsherbiny et al., 2013).

In addition, increased ENT1 was previously demonstrated in human aortic smooth muscle cells by hyperglycemia (Leung et al., 2005). Similar to this study, we found increased ENT1 protein and mRNA levels in mouse retina with TON (Fig. 3). AKI treatment attenuated its expression level in retinal tissue. ENT1 transports adenosine from intercellular to extracellular and vice versa. Previously it was reported that ENT1 expression was increased in high glucose (Liou, 2010), which may affect the availability of adenosine for its receptor to work as anti-inflammatory in diabetes. Thus, we may say that in TON ENT1 up-regulation is pathologically implicated and causes low concentration of adenosine by reuptake intercellular, but its low expression may be beneficial in TON. This result is supported by our recent work where we have shown that ABT-702 markedly decreased ENT1 expression in diabetic retinopathy (Elsherbiny et al., 2013).

Further, we investigated the effect of ABT-702 treatment on TON induced oxidative stress. We previously demonstrated increased oxidative stress in mice retina with TON (Ahmad et al., 2013). Here, we studied the effect of ABT-702 treatment on superoxide anion, iNOS/nNOS and nitrotyrosine levels in mice retina with TON. Nitration of tyrosine residues is evident in several retinal inflammatory and neurodegenerative diseases (Gouder et al., 2004), which occurs due to reaction of tyrosine with reactive nitrogen species such as peroxynitrite (Pacher et al., 2007). These reactive nitrogen species are formed by reaction of superoxide anion and Nitric oxide (NO), thus, serving as a likely indicator simultaneous generation of NO and superoxide (El-Remessy et al., 2003). However, It is reported that retinal ganglion cell loss during retinal hypoxia regulated by NO (Kaur et al., 2006). Under pathological conditions, NO is synthesized by the inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS). Studies reported the expression of nNOS and iNOS in glial cells, infiltrating leukocytes and in RGCs in hypoxic retina (Kashiwagi et al., 2003; Kaur et al., 2006). The produced NO from nNOS and iNOS contributes to neurotoxicity resulting in cell death and axonal damage (Kaur et al., 2008). Report suggests that NO triggered several pathways including N-methyl-D-aspartate (NMDA)-mediated intracellular Ca^{2+} influx and CREB-mediated apoptotic proteins which results to neuronal death (Mishra et al., 2002). Increased NO production is shown to mediate MAPKinase activation during hypoxia in cerebral cortical nuclei of




Fig. 8. Proposed possible molecular mechanism of anti-inflammation in Traumatic Optic Neuropathy.

newborn piglets (Mishra et al., 2004). In the current study, we found increased levels of iNOS/nNOS expression in TON retinal tissue, and increased superoxide anion and nitrotyrosine levels in mouse retinal sections with TON. Treatment with ABT702 attenuated TON-induced oxidative and nitrate stress in mouse retina with TON. These findings suggested that ABT 702 attenuated TON-induced activated microglia production of NO and reactive oxygen species by augmenting adenosine signaling.

We investigated the role of ABT 702 treatment in MAPKinase activation in mouse microglia in vitro. In Fig. 7D immunocytochemistry results revealed that Iba1 and p-ERK1/2 co-localized in LPS-induced mouse microglia. In our previous study we have reported that LPS activates ERK1/2 phosphorylation (Ahmad et al., 2013). Using mouse microglia cells we have shown that LPS treatment induces pERK1/2 and p-P38 MAPKinase activation, which leads to increased TNF- α release. Activation of MAPKinase has been demonstrated as a major signaling cascade for TNF- α production in microglia (Ajizian et al., 1999). In this study, data shows that AKI treatment reduced the phosphorylation of ERK and P38 in microglia cells. This result was an agreement with our previous finding where A_{2A}AR agonist attenuated increased TNF- α release in activated microglial cells through MAP Kinase pathway (Ahmad et al., 2013).

In conclusion we may demonstrate that inhibition of adenosine kinase attenuates TON-induced inflammation and neurotoxicity by stimulating adenosine signaling and inhibiting MAPKinase pathway in activated retinal microglia cells (Fig. 8).

Disclosure

This report is according to journal guidelines and ethical issues. All authors have no conflicts of interest.

Acknowledgments

This work has been supported by the U.S. Department of Defense (Grant number-DM102155) and Vision Discovery Institute (VDI) at GRU, Augusta, GA, USA to GIL.

References

- Ahmad, S., Fatteh, N., El-Sherbiny, N.M., Naime, M., Ibrahim, A.S., El-Sherbiny, A.M., El-Shafey, S.A., Khan, S., Fulzele, S., Gonzales, J., Liou, G.I., 2013. Potential role of A_{2A} adenosine receptor in traumatic optic neuropathy. *J. Neuroimmunol.* 264, 54–64.
- Ajizian, S.J., English, B.K., Meals, E.A., 1999. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible

- nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. *J. Infect. Dis.* 179, 939–944.
- Annes, J.P., Ryu, J.H., Lam, K., Carolan, P.J., Utz, K., Hollister-Lock, J., Arvanites, A.C., Rubin, L.L., Weir, G., Melton, D.A., 2012. Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication. *Proc. Natl. Acad. Sci. U. S. A.* 109, 3915–3920.
- Boison, D., 2008. Adenosine as a neuromodulator in neurological diseases. *Curr. Opin. Pharmacol.* 8, 2–7.
- Boison, D., Shen, H.Y., 2010. Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. *Open Drug Discov. J.* 2, 108–118.
- El-Remessy, A.B., Abou-Mohamed, G., Caldwell, R.W., Caldwell, R.B., 2003. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. *Invest. Ophthalmol. Vis. Sci.* 44, 3135–3143.
- Elsherbiny, N.M., Ahmad, S., Naime, M., Elsherbiny, A.M., Fulzele, S., Al-Gayyar, M.M., Eissa, L.A., El-Shishtawy, M.M., Liou, G.I., 2013. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. *Life Sci.* 93, 78–88.
- Fredholm, B.B., Chen, J.F., Cunha, R.A., Svenningsson, P., Vaugeois, J.M., 2005. Adenosine and brain function. *Int. Rev. Neurobiol.* 63, 191–270.
- Gouder, N., Scheurer, L., Fritschy, J.M., Boison, D., 2004. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. *J. Neurosci.* 24, 692–701.
- Hagberg, H., Andersson, P., Lacarewicz, J., Jacobson, I., Butcher, S., Sandberg, M., 1987. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. *J. Neurochem.* 49, 227–231.
- Ibrahim, A.S., El-Shishtawy, M.M., Zhang, W., Caldwell, R.B., Liou, G.I., 2011. A(2)A adenosine receptor (A(2)A)AR as a therapeutic target in diabetic retinopathy. *Am. J. Pathol.* 178, 2136–2145.
- Kashiwagi, K., Iizuka, Y., Mochizuki, S., Tsumamoto, Y., Mishima, H.K., Araie, M., Suzuki, Y., Tsukahara, S., 2003. Differences in nitric oxide production: a comparison of retinal ganglion cells and retinal glial cells cultured under hypoxic conditions. *Brain Res. Mol. Brain Res.* 112, 126–134.
- Kaur, C., Sivakumar, V., Foulds, W.S., 2006. Early response of neurons and glial cells to hypoxia in the retina. *Invest. Ophthalmol. Vis. Sci.* 47, 1126–1141.
- Kaur, C., Foulds, W.S., Ling, E.A., 2008. Hypoxia–ischemia and retinal ganglion cell damage. *Clin. Ophthalmol.* 2, 879–889.
- Leung, G.P., Man, R.Y., Tse, C.M., 2005. D-Glucose upregulates adenosine transport in cultured human aortic smooth muscle cells. *Am. J. Physiol. Heart Circ. Physiol.* 288, H2756–H2762.
- Liou, G.I., 2010. Diabetic retinopathy: role of inflammation and potential therapies for anti-inflammation. *World J. Diabetes* 1, 12–18.
- Lucas, S.M., Rothwell, N.J., Gibson, R.M., 2006. The role of inflammation in CNS injury and disease. *Br. J. Pharmacol.* 147 (Suppl. 1), S232–S240.
- Lusardi, T.A., 2009. Adenosine neuromodulation and traumatic brain injury. *Curr. Neuropharmacol.* 7, 228–237.
- Meno, J.R., Ngai, A.C., Ibayashi, S., Winn, H.R., 1991. Adenosine release and changes in pial arteriolar diameter during transient cerebral ischemia and reperfusion. *J. Cereb. Blood Flow Metab.* 11, 986–993.
- Mishra, O.P., Ashraf, Q.M., Delivoria-Papadopoulos, M., 2002. Phosphorylation of cAMP response element binding (CREB) protein during hypoxia in cerebral cortex of newborn piglets and the effect of nitric oxide synthase inhibition. *Neuroscience* 115, 985–991.
- Mishra, O.P., Zubrow, A.B., Ashraf, Q.M., 2004. Nitric oxide-mediated activation of extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) during hypoxia in cerebral cortical nuclei of newborn piglets. *Neuroscience* 123, 179–186.
- Moser, G.H., Schrader, J., Deussen, A., 1989. Turnover of adenosine in plasma of human and dog blood. *Am. J. Physiol.* 256, C799–C806.
- Pacher, P., Beckman, J.S., Liaudet, L., 2007. Nitric oxide and peroxynitrite in health and disease. *Physiol. Rev.* 87, 315–424.
- Pang, T., Gan, X.T., Freeman, D.J., Cook, M.A., Karmazyn, M., 2010. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. *Am. J. Physiol. Heart Circ. Physiol.* 298, H545–H553.
- Phillis, J.W., Walter, G.A., Simpson, R.E., 1991. Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycytidine. *J. Neurochem.* 56, 644–650.
- Shen, H.Y., Singer, P., Lytle, N., Wei, C.J., Lan, J.Q., Williams-Karnesky, R.L., Chen, J.F., Yee, B.K., Boison, D., 2012. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. *J. Clin. Invest.* 122, 2567–2577.
- Smith, J.A., Das, A., Ray, S.K., Banik, N.L., 2012. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res. Bull.* 87, 10–20.
- Steinsapir, K.D., Goldberg, R.A., 2011. Traumatic optic neuropathy: an evolving understanding. *Am. J. Ophthalmol.* 151 (928–933), e922.
- Tatlisumak, T., Takano, K., Carano, R.A., Miller, L.P., Foster, A.C., Fisher, M., 1998. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. *Stroke* 29, 1952–1958.
- Ugarkar, B.G., Castellino, A.J., DaRe, J.M., Kopcho, J.J., Wiesner, J.B., Schanzer, J.M., Erion, M.D., 2000. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. *J. Med. Chem.* 43, 2894–2905.
- Vlajkovic, S.M., Guo, C.X., Telang, R., Wong, A.C., Paramanathasivam, V., Boison, D., Housley, G.D., Thorne, P.R., 2011. Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss. *Exp. Gerontol.* 46, 905–914.
- White, T.D., 1996. Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. *Eur. J. Pharmacol.* 303, 27–38.
- Williams, M., 1996. Challenges in developing P2 purinoceptor-based therapeutics. *Ciba Found. Symp.* 198, 309–321.
- Zheng, Z., Yuan, R., Song, M., Huo, Y., Liu, W., Cai, X., Zou, H., Chen, C., Ye, J., 2012. The toll-like receptor 4-mediated signaling pathway is activated following optic nerve injury in mice. *Brain Res.* 1489, 90–97.



ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy

Nehal M. Elsherbiny^{a,c}, Saif Ahmad^a, Mohammad Naime^a, Ahmed M. Elsherbini^a, Sadanand Fulzele^b, Mohammed M. Al-Gayyar^c, Laila A. Eissa^c, Mamdouh M. El-Shishtawy^c, Gregory I. Liou^{a,*}

^a Department of Ophthalmology, Georgia Regents University, 30909, USA

^b Department of Orthopedics, Georgia Regents University, 30909, USA

^c Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura University, 35516, Egypt

ARTICLE INFO

Article history:

Received 25 January 2013

Accepted 28 May 2013

Keywords:

Diabetic retinopathy

Inflammation

Adenosine kinase

ABSTRACT

Aims: This study was undertaken to determine the effect of an adenosine kinase inhibitor (AKI) in diabetic retinopathy (DR). We have shown previously that adenosine signaling via A_{2A} receptors ($A_{2A}AR$) is involved in retinal protection from diabetes-induced inflammation. Here we demonstrate that AKI-enhanced adenosine signaling provides protection from DR in mice.

Main methods: We targeted AK, the key enzyme in adenosine metabolism, using a treatment regime with the selective AKI, ABT-702 (1.5 mg/kg intraperitoneally twice a week) commencing at the beginning of streptozotocin-induced diabetes at the age of eight weeks. This treatment, previously demonstrated to increase free adenosine levels in vivo, was maintained until the age of 16 weeks. Retinal inflammation was evaluated using Western blot, Real-Time PCR and immuno-staining analyses. Role of $A_{2A}AR$ signaling in the anti-inflammation effect of ABT-702 was analyzed in Amadori-glycated-albumin (AGA)-treated microglial cells.

Key findings: At 16 weeks, when diabetic mice exhibit significant signs of retinal inflammation including up-regulation of oxidative/nitrosative stress, $A_{2A}AR$, ENT1, Iba1, TNF- α , ICAM1, retinal cell death, and down-regulation of AK, the ABT-702 treated group showed lower signs of inflammation compared to control animals receiving the vehicle. The involvement of adenosine signaling in the anti-inflammation effect of ABT-702 was supported by the TNF- α release blocking effect of $A_{2A}AR$ antagonist in AGA-treated microglial cells.

Significance: These results suggest a role for AK in regulating adenosine receptor signaling in the retina. Inhibition of AK potentially amplifies the therapeutic effects of site- and event-specific accumulation of extracellular adenosine, which is of highly translational impact.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Diabetic retinopathy (DR) is the leading cause of acquired vision loss among adults of working age in developed countries worldwide and has been perceived as the most common microvascular complication of diabetes (Zhu and Zou, 2012). Despite many years of research, treatment options for DR, including photocoagulation, vitrectomy and repeated intraocular injections of steroids and anti-vascular endothelial growth factor (VEGF), remain invasive, limited and with adverse effects. This is because VEGF, although induces angiogenesis, is also required for the maintenance of retinal neurons. By neutralizing VEGF with anti-VEGF, angiogenesis could be solved at the expense of neuronal degeneration. Therefore, there is a great need for the development of new non-invasive therapies.

The early signs of DR in experimental diabetic models include vascular inflammatory reactions due to oxidative stress, pro-inflammatory cytokines, and the consequent upregulation of leukocyte adhesion molecules (Tang and Kern, 2011). These reactions lead to breakdown of the blood–retinal barrier, vascular occlusion and tissue ischemia, which in turn leads to neuronal cell death (El-Remessy et al., 2006). Under these conditions, normally quiescent microglial cells become activated. Activated microglia release reactive oxygen species and proinflammatory mediators, such as tumor necrosis factor TNF- α (Xie et al., 2002). Thus, research on retinal microglia activation may provide insights into the pathogenesis of DR (Ibrahim et al., 2011a).

Adenosine is centrally involved in the signaling cascade of related events, including anti-inflammatory actions, angiogenesis, oxygen supply/demand ratio, and ischemic pre- and postconditioning (Johnston-Cox and Ravid, 2011). Under these circumstances, the local levels of extracellular adenosine are increased due to the increased need for energy supplied by ATP (Vallon et al., 2006). The increased extracellular adenosine at inflamed sites can protect against cellular damage by activating the A_{2A} adenosine receptor ($A_{2A}AR$), a Gs-coupled

* Corresponding author at: Department of Ophthalmology, Georgia Health Sciences University, 1120 15th Street, Augusta, GA 30912, USA. Tel.: +1 706 721 4599.

E-mail address: giliou@gru.edu (G.I. Liou).

receptor (Ibrahim et al., 2011b). Extracellular adenosine re-uptake by the equilibrative and concentrative nucleoside transporters (ENT and CNT) allows for adenosine conversion to AMP by adenosine kinase (AK) (Löffler et al., 2007), decreases extracellular adenosine levels, and terminates the protective effect of A_{2A} AR. The removal of extracellular adenosine is predominantly regulated by AK via conversion of adenosine into AMP. The extracellular levels of adenosine are largely dependent on the intracellular activity of AK whereas the degradation of adenosine into inosine by adenosine deaminase (ADA) plays only a minor role in regulating adenosinergic function (Pak et al., 1994).

We aim to evaluate the AK in regulating adenosine signaling in the retina. It was reported that the degree of brain injury directly depends on expression levels of AK and the resulting extracellular levels of adenosine (Boison, 2006). Indeed, transgenic mice overexpressing AK are highly susceptible to stroke-induced brain injury (Shen et al., 2011). We therefore hypothesized that adenosine kinase inhibitors (AKI) could play the same protective role in the diabetic retina.

Methods

Preparation of AKI

A selective AKI, 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-dipyrimidine (ABT-702, 5 mg) from Santa Cruz was dissolved in 0.25 mL of DMSO (20 mg/mL) and then in 9.75 mL of distilled water to prepare a 0.5 mg/mL stock solution. The solutions were aliquoted and stored at -20°C for later use. An equivalent volume of vehicle solution was administered to the control animals. ABT-702 was used previously to study the effect of AK inhibition on neuronal inflammation (Suzuki et al., 2001) and age-related hearing loss (Vlajkovic et al., 2011). ABT-702 was 1300- to 7700-fold selective for AK compared with a number of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including cyclooxygenases-1 and -2 (Jarvis et al., 2000).

Animal preparation and experimental design

All procedures with animals were performed in accordance with the Public Health Service Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and Welfare, National Institutes of Health Publication No. 80-23) and the Georgia Health Sciences University guidelines. Male, eight-week-old mice in C57BL/6J (Jackson Laboratory, Bar Harbor, ME) background were used. Animals were given i.p. injections of vehicle or freshly prepared streptozotocin in 0.01 mol/L sodium citrate buffer, pH 4.5 (45 mg/kg) after a 4-hour fast each day for 5 consecutive days. Diabetes was confirmed by fasting blood glucose levels >250 mg/dL. The diabetic and normal, non-diabetic mice were randomly divided into four subgroups: ABT-702-treated diabetic, ABT-702-treated normal, vehicle-treated diabetic and vehicle-treated normal (1.5 mg/kg intraperitoneally, twice a week).

Eight weeks after the establishment of diabetes, the retinas were removed, snap frozen in liquid nitrogen, stored at -80°C , and analyzed by Quantitative Real Time-PCR (qRT-PCR) or Western blot. Frozen eye sections were prepared for immunofluorescence or immunohistochemistry.

Measurement of blood glucose

Blood glucose was measured by blood glucose meter (OneTouch UltraEasy, USA).

Primary retinal microglia culture

Microglial cells were isolated from retinas of newborn Sprague Dawley (SD) rats according to a previous procedure (El-Remessy

et al., 2008) with minor modifications. Briefly, retinas were collected into phosphate-buffered saline and digested with 0.125% trypsin for 3–5 min before mixing with Dulbecco's Modified Eagle Medium (DMEM)/F12 containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Retina pieces were then filtered through a mesh (100 μm), collected by centrifugation, resuspended in culture medium and plated onto T75 cell culture flasks (Corning, NY) at a density of 2×10^5 cells/cm². After 2 weeks, microglial cells were harvested by shaking the flasks at 100 rpm for 1 h. Immunocytochemical studies showed that more than 95% cultured cells stained positively for Iba1. Almost none of these cells showed positive staining for GFAP, indicating that majority of the isolated cells were microglia and were not contaminated with astrocytes or Müller cells (data not shown).

Drug treatment effects on cultured microglial cells

Microglial cells were seeded at a density of 5×10^5 cells/well in a collagen-1-pretreated 24-well tissue culture plate. One day after seeding, the cultured wells were washed with Cellgro Complete (Mediatech, Manassas, VA) and incubated in the same media with various treatments. Cells were pretreated with AR antagonists (all are from Sigma-Aldrich except ZM 241385, which is from Tocris) at the indicated concentrations for 30 min at 37°C , followed with ABT-702 or vehicle for 30 min at 37°C . Microglial activation was then achieved by addition of Amadori-glycated albumin (AGA; Sigma) with undetectable endotoxin (<0.125 units/mL, 10 EU = 1 ng lipopolysaccharide; Lonza, Basel, Switzerland) (Ibrahim et al., 2011a) to each well at a final concentration of 250 or 500 $\mu\text{g/mL}$ at indicated time points (Ibrahim et al., 2011a,b). After the indicated time course, culture media were collected and assayed for TNF- α by ELISA.

ELISA for TNF- α

TNF- α levels in the supernatants of culture media were estimated with ELISA kits (R & D, Minneapolis, MN) per the manufacturer's instructions. Standards and samples were added and bound by the immobilized antibody. After washing an enzyme-linked polyclonal antibody specific for the cytokine was added to the wells followed by a substrate solution yielding a colored product. The intensity of the color was measured at 450 nm. The sample levels were calculated from the standard curve and corrected for protein concentration.

Quantitative real time-PCR

Total RNA was isolated from mouse retina using SV Total RNA Isolation kit (Promega, Madison, WI) following manufacturer's instructions, and the quality of the RNA preparations was monitored by absorbance at 260 and 280 nm (Helios-Gamma, Thermo Spectronic, Rochester, NY). The RNA was reverse-transcribed into complementary deoxyribonucleic acid (cDNA) using iScript reagents from Bio-Rad on a programmable thermal cycler (PCR-Sprint, Thermo Electron, Milford, MA). Fifty ng of cDNA was amplified in each qRT-PCR using a Bio-Rad iCycler, ABgene reagents (Fisher scientific) and appropriate primers (Table 2). Average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA was used as the internal control for normalization.

Western blot analysis

Dissected individual mouse retinas were homogenized in modified RIPA buffer (Upstate, Lake Placid, NY), containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% deoxycholate, supplemented with 40 mM NaF, 2 mM Na_3VO_4 , 0.5 mM phenylmethylsulfonyl fluoride and 1:100 (v/v) of proteinase inhibitor cocktail (Sigma). Insoluble material was removed by centrifugation at 12,000 $\times g$ at 4°C for 30 min. Protein was determined by DC Protein

Table 1
Body weight and blood glucose levels in studied groups.

Group	No	Body weight (g)		Blood glucose (mg/dL)	
Non-diabetic	7	30.8	0.59	198.6	11.61
Non-diabetic + ABT 7002	7	30.0	0.67	198.6	7.93
Diabetic	7	24.1**	0.61	399.6***	11.22
Diabetic + ABT 702	7	23.4**	0.57	373.5***	6.82

Mean \pm SD.

** $P < 0.001$ vs non-diabetic group.

*** $P < 0.0001$ vs non-diabetic group.

Assay (Bio-Rad, Hercules, CA) and 100 μ g was boiled in Laemmli sample buffer, separated by SDS-PAGE on a gradient gel (4 to 20%) (Pierce, Rockford, IL), transferred to nitrocellulose membrane and incubated with specific antibodies. Antibodies for β -actin, ICAM-1, ENT1, A_{2A} AR and AK (Santa Cruz Biotechnology, Santa Cruz, CA) were detected with a horseradish peroxidase-conjugated antibody and enhanced chemiluminescence (ECL) (Amersham BioSciences, Buckinghamshire, UK). The same filter was re-probed with control antibodies, such as those for the actin. Intensity of immunoreactivity was measured by densitometry.

Immunolocalization studies

Immunofluorescence analysis was performed using frozen eye sections. Briefly, cryostat sections (7 μ m) were fixed in 4% paraformaldehyde, blocked with Dako protein block serum-free and then incubated overnight at 4 °C with primary antibodies: rabbit anti-Iba-1 (Proteintech Group), or goat anti-ICAM-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-AK (Santa Cruz Biotechnology, Santa Cruz, CA). Thereafter, sections were briefly washed with PBS and incubated with appropriate secondary antibodies. Slides were examined by fluorescent microscope. Specificity of the reaction was confirmed by omitting the primary antibody, or by using non-immune IgG.

Immunohistochemistry of cleaved, activated caspase-3 was performed as follows. Retinas frozen sections were fixed in 4% paraformaldehyde, rinsed in PBS, blocked with 0.3% H_2O_2 then Mouse on Mouse (M.O.M.) Immunoglobulin Blocking Solution (Vector Laboratories, Burlingame, CA), and reacted with antibodies detecting cleaved, activated caspase-3 (Cell Signaling Technology) for 16 to 20 h at room temperature. Sections were washed, and reacted with M.O.M. biotinylated anti-mouse Ig reagent (1:250), followed by M.O.M. ABC reagent. Color was developed with 3,3'-diaminobenzidine (DAB) as substrate.

Terminal dUTP nick end-labeling (TUNEL)

TUNEL was performed in frozen sections using the TACS-2 TdT Fluorescein In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg,

Table 2
The primer sets used for the detection of mouse genes by quantitative Real-Time PCR analysis.

Gene	Primer sequence (5'–3')	Accession number
TNF- α	CCCTCACACTCAGATCATCTTCT GTCACGACGTGGGCTACAG	NM_013693.2
ICAM-1	CGCTGTGCTTTGAGAACTGTG ATACACGGTGATGGTAGCGGA	NM_010493
Iba-1	GTCCTTGAAGCGAATGCTGG CATCTCAAGATGCCAGATC	NM_019467
GAPDH	CAT GGC CTC CAA GGA GTAAGA GAG GGA GAT GCT CAG TGT TGG	M32599
18S	AGT GCG GGT CAT AAG CTT GC GGG CCT CAC TAA ACC ATC CA	NR_003278

MD) counter-stained with propidium iodide, according to the manufacturer's suggestions. Briefly, sections were hydrated with alcohol 100%, 95%, and 70%, and then fixed in 3.7% paraformaldehyde. After washing, slides were incubated in mixture of TdT, Mn + 2, and TdT dNTP for 1 h at 37 °C. The reaction was stopped with TdT Stop Buffer for 5 min. After washing with deionized water, the slides were incubated with Streptavidin–HRP (diluted 1:200) solution for 20 min at room temperature. Slides were counter-stained, mounted, covered with coverslips and visualized by confocal microscopy (LSM 510, Carl Zeiss, Inc.). Apoptotic cells were identified as doubly labeled with TdT Fluorescein and propidium iodide and only nuclei that were clearly labeled yellow were scored.

Measurement of oxidative and nitrosative stress

The production of superoxide as oxidative stress, and peroxynitrite as nitrosative stress were measured in frozen eye sections using the oxidative fluorescent dye dihydroethidium (DHE) and nitrotyrosine immunofluorescent staining, respectively. DHE (2 μ M) (Sigma-Aldrich, Oakville, ON, Canada) was applied to 7 μ m thick eye sections and the slides were then incubated in a light protected humidified chamber at 37 °C for 30 min. Cells are permeable to DHE. In the presence of superoxide, DHE is oxidized to fluorescent ethidium, which is trapped by intercalation with DNA. Ethidium is excited at 518 nm with an emission spectrum of 605 nm. The intensity of the fluorescence was quantified by Image J software (version 1.42; National Institutes of Health, Bethesda, MD). Nitrotyrosine levels in frozen eye sections were quantified by immunofluorescent histochemistry. Sections were stained with antibody for nitrotyrosine (Santa Cruz Biotechnology, Santa Cruz, CA). Images were observed using fluorescent microscope.

Data analysis

The results are expressed as mean \pm SD. Differences among experimental groups were evaluated by analysis of variance, and the significance of differences between groups was assessed by the posthoc test (Fisher's PLSD). Significance was defined as $P < 0.05$.

Results

Body weight and blood glucose levels in studied group

The final body weight was lower after streptozotocin injection, and it was not affected by ABT 702 treatment. Blood glucose levels were higher in diabetic mice compared with non-diabetic groups and they were not modified by ABT-702 treatment (Table 1).

Inhibition of adenosine kinase mitigates retinal inflammation in diabetic mice

Inflammation has been proposed to be important in the pathogenesis of DR. An early feature of inflammation is the release of cytokines leading to increased expression of endothelial activation markers such as Intercellular Adhesion Molecule 1 (ICAM-1) (Rangasamy et al., 2012). Consistently, ICAM-1 and TNF- α expressions were markedly increased in the retinas of 8-week diabetic mice as compared with normal, non-diabetics as revealed by qRT-PCR (Fig. 1A, B) and Western analyses (Fig. 1C). Treatment with ABT 702 (1.5 mg/kg i.p., twice a week) reduced retinal ICAM-1 expression and retinal TNF- α in the diabetic mice as compared with vehicle-treated diabetic mice.

Inhibition of adenosine kinase blocks A_{2A} AR up-regulation in diabetic mice

A_{2A} AR is the most likely candidate for mediating the anti-inflammatory effect of adenosine (Milne and Palmer, 2011). Diabetes




Fig. 1. Inhibition of adenosine kinase mitigates retinal inflammation in diabetic mice. A, B) Retinal expression of ICAM1 and TNF- α measured by R-T PCR. A) Effect of AK inhibition on ICAM1 expression in the diabetic mouse retina. B) Effect of AK inhibition on TNF- α expression in the diabetic mouse retina. GAPDH and 18S were used as reporter genes. The results represent the means \pm SD of fold changes calculated using expression level, normalized to the level of the normal non-diabetic mice (n = 4–6). C) Representative Western blots and quantitative analysis of retinal ICAM1 expression showing the effect of AK inhibition on ICAM-1 expression in the diabetic mouse retina (n = 4).

or inflammation is associated with up-regulation of $A_{2A}AR$ (Pang et al., 2010). The increased $A_{2A}AR$ expression may possibly represent an endogenous mechanism to combat the inflammation associated with diabetes induction. Consistent with this, diabetes induced up-regulation of $A_{2A}AR$ in the retina as compared with normal (Fig. 2). Treatment of ABT 702 reduced $A_{2A}AR$ expression in the diabetic mice as compared with vehicle-treated diabetic mice (Fig. 2).




Fig. 2. Inhibition of adenosine kinase blocks $A_{2A}AR$ up-regulation in diabetic mice. Representative Western blots and quantitative analysis of retinal $A_{2A}AR$ expression showing the effect of AK inhibition on $A_{2A}AR$ expression in the diabetic mouse retina (n = 4).

Inhibition of adenosine kinase blocks ENT1 up-regulation in diabetic mice

ENT1 plays an integral role in adenosine function in diabetes by regulating adenosine levels in the vicinity of adenosine receptors. Hyperglycemia up-regulated ENT1 expression and adenosine transport in cultured human aortic smooth muscle cells (Leung et al., 2005). Consistent with this observation, diabetes induced up-regulation of ENT1 in the retina as compared with normal (Fig. 3). The increase in ENT1 activity in diabetes may affect the availability of adenosine in the vicinity of adenosine receptors and, thus, alter vascular functions in diabetes. Treatment with ABT 702 reduced ENT1 expression in diabetic mice as compared with vehicle-treated diabetic mice (Fig. 3).




Fig. 3. Inhibition of adenosine kinase blocks ENT1 up-regulation in diabetic mice. Representative Western blots and quantitative Western analysis of retinal ENT1 expression showing the effect of AK inhibition on ENT1 expression in the diabetic mouse retina (n = 4).

Inhibition of adenosine kinase blocks adenosine kinase down-regulation in diabetic mice

Sakowicz and Pawelczyk reported reduced AK activity in tissues of diabetic rat. They suggested that the expression of AK to some extent is controlled by insulin. Reduced AK expression is also reported in hypoxic tissues (Morote-Garcia et al., 2008). The reduced AK expression may possibly represent an endogenous protective mechanism to raise extracellular adenosine levels. Consistent with these observations, AK expression was reduced in retinas of diabetic mice as compared with the normal (Fig. 4A, B). Treatment with ABT 702 blocked the diabetic effect on AK in diabetic mice as compared with vehicle-treated diabetic mice (Fig. 4A, B).

Inhibition of adenosine kinase mitigates retinal microglial activation in diabetic mice

We next sought to explore a potential mechanism by which ABT702 regulates inflammation in DR. Through immunofluorescence, the effect of ABT702 treatment on microglial activation was determined by measuring Iba1 expression, which is up-regulated in activated microglia in diabetic mice as compared with normal. Iba1 was found to be decreased in the AKI-treated diabetic mice as compared

with vehicle-treated diabetic mice (Fig. 5A). In addition, the level of Iba1 mRNA was markedly reduced in the retinas of AKI-treated diabetic mice as compared with vehicle-treated diabetic mice (Fig. 5B).

Inhibition of adenosine kinase mitigates oxidative and nitrosative stress in the retina of diabetic mice

Oxidative stress is a key pathogenic factor in DR (Madsen-Bouterse and Kowluru, 2008). Diabetic mice showed a significant increase in DHE staining as compared with normal group and treatment with ABT 702 reduced DHE staining in diabetic mice retinas as compared with vehicle-treated diabetic mice (Fig. 6A). In addition, immunofluorescent staining of nitrotyrosine, a stable product formed from the reaction of peroxynitrite with tyrosine residues and an index of nitrosative damage, was elevated in the retinas of diabetic mice as compared with that in normal retinas. ABT702-treated diabetic mice showed decreased nitrotyrosine staining as compared with vehicle-treated diabetic mice (Fig. 6B).

Inhibition of adenosine kinase reduces retinal cell death in diabetic mice

Retinal cell death in diabetic and non-diabetic animals treated and untreated with ABT702 was determined by immunostaining of cleaved,




Fig. 4. Inhibition of adenosine kinase blocks adenosine kinase down-regulation in diabetic mice. A) Western blot analysis. B) Immunofluorescence staining. Arrows indicate AK distribution (n = 4–6).




Fig. 5. Inhibition of adenosine kinase mitigates retinal microglial activation in diabetic mice. A) Effect of AK inhibition on Iba1 expression in the diabetic mouse retina determined by immunofluorescence staining. Scale bar: 20 μ m; B) determined by RT PCR analysis; GAPDH and 18S were used as reporter genes. The results represent the means \pm SE of fold changes calculated using expression level, normalized to the level of the normal non-diabetic mice (n = 4–6).

activated caspase-3, a known marker for apoptosis, and by TUNEL. As shown by these methods, increased cell death appeared in the retinal ganglion cell layer of diabetic animals (Fig. 7A, B). Treatment with ABT702 blocked cell death in diabetic mice but did not affect treated normal controls (Fig. 7A, B). Taken together, the above findings suggest that AK inhibition plays a role in attenuating retinal oxidative stress, inflammation, and cell death by dampening microglial cell activation.

Inhibition of adenosine kinase is more effective than adenosine deaminase in blocking TNF- α release in activated retinal microglial cells

The extracellular levels of adenosine are largely dependent on the intracellular activity of AK whereas the degradation of adenosine into inosine by adenosine deaminase (ADA) plays only a minor role in regulating adenosinergic function (Pak et al., 1994). This was further confirmed by others: endogenous adenosine levels in the brain are mainly dependent on the activity of AK (Gouder et al., 2004). To compare the anti-inflammatory effect of the inhibitors of AK and ADA, we developed a cultured retinal microglia model. This model also helps elucidate the molecular mechanisms responsible for this effect. In this model, we determined the ability of ABT702 and EHNA, an ADA inhibitor, to affect TNF- α release in retinal microglia in response to AGA treatment. EHNA at levels comparable to the present study was previously used to study the cardioprotective effect of adenosine metabolism inhibitors (Peart et al., 2001). Microglial cells were pretreated with the indicated concentrations of ABT702 and EHNA for 1/2 h then treated with AGA for 16 h. The supernatants were collected and assayed for TNF- α by ELISA. As shown (Fig. 8), ABT 702 inhibited AGA-induced

TNF- α release in a dose-dependent manner more significantly than EHNA.

Inhibition of adenosine kinase blocks TNF- α release via A_{2A} AR

To identify the AR subtype(s) involved in ABT 702 inhibitory effect on TNF- α release in the retinal microglia in response to AGA, we examined the effect of the ABT 702 in the presence of AR subtype-selective antagonists. The concentrations of each antagonist chosen for this study were based on the affinity and selectivity for the recombinant mouse AR subtypes determined by radioligand binding studies, and was applied to rat retinal microglial cells previously (Liou et al., 2008; Ibrahim et al., 2011b). As shown in Fig. 9, cells pretreated with vehicle showed a significant increase in AGA-induced TNF- α release compared with vehicle-treated control cells. Treatment with ABT 702 at a concentration of 20 μ M potently inhibited AGA-induced TNF- α release. When the cells were pretreated with the A_{1A} AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (CPX; 100 nM), the A_{2B} AR antagonist 8-[4-[(4-cyanophenyl) arbamoylmethyl] oxy] phenyl]-1,3-di(n-propyl) xanthine hydrate (MRS 1754; 1 μ M), or the A_{3A} AR antagonist 3-propyl-6-ethyl-5 [(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate (MRS 1523; 10 μ M), the inhibitory effect of ABT 702 on TNF- α release was not affected. However, this effect was successfully blocked by 4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3- α][1,3,5]triazin-5-ylamino]ethyl] phenol (ZM 241385) at concentrations (100 and 500 nM) capable of blocking A_{2A} ARs. These results suggest that ABT 702 inhibited AGA-induced TNF- α release from retinal microglia via the A_{2A} AR.




Fig. 6. Inhibition of adenosine kinase mitigates oxidative and nitrosative stress in the retina of diabetic mice. Effect of AK inhibition on diabetes-induced oxidative and nitrosative stress in the retina. A) Oxidative stress measured by DHE staining. The fluorescence intensity indicates the level of superoxides production. The results represent the means \pm SE of fold changes calculated using intensity, normalized to the level of the normal non-diabetic mice ($n = 4-6$). B) Nitrosative stress determined by immunofluorescence for nitrotyrosine. Scale bar: 20 μ m.

Discussion

Biochemical studies have shown that inflammatory reactions (Joussen et al., 2004), including TNF- α release, are relatively early events that occur in response to diabetes before vascular dysfunction involving acellular capillary formation and neovascularization (Kern and Barber, 2008). Moreover, TNF- α has been shown to recruit leukocytes, cause vascular breakdown and promote neuronal injury at high levels (Joussen et al., 2009). Thus, treatments targeting early features of DR would provide long-term vascular benefits. Adenosine released

at inflamed sites exhibits anti-inflammatory effects through $A_{2A}AR$ (Bong et al., 1996). Although adenosine and its agonists are protective in animal models of inflammation, their therapeutic application has been limited by systemic side effects such as hypotension, bradycardia, and sedation (Williams, 1996). Moreover, adenosine usually disappears very rapidly in physiological or inflammatory conditions due to rapid re-uptake and subsequent intracellular metabolism (Möser et al., 1989). The use of AK inhibitors represents one possible way to amplify the endogenous therapeutic effects of site- and event-specific accumulation of extracellular adenosine while minimizing hemodynamic toxicity.




Fig. 7. Inhibition of adenosine kinase reduces retinal cell death in diabetic mice. A) Representative images with arrows show the localization of the apoptotic marker cleaved, activated caspase-3 in the ganglion cell layer in diabetic retina sections. ABT702 attenuated diabetes-induced cell death in the retina. B) Representative images with arrows showing the localization and quantitative analysis of TUNEL-positive cells in the ABT702-treated diabetic mice. The results represent the means \pm SE of TUNEL-positive cells per retinal cross section ($n = 4$).

Endogenous adenosine levels in the brain are mainly dependent on the activity of AK, the key enzyme of adenosine metabolism (Gouder et al., 2004). This notion is based on several lines of evidence: 1) transgenic mice overexpressing AK are highly susceptible to stroke-induced brain injury (Pignataro et al., 2007); 2) pharmacological inhibition of AK provides seizure suppression in various models of epilepsy (Ugarkar et al., 2000); 3) inhibition of AK in hippocampal slices

increases endogenous adenosine and depresses neuronal firing, whereas inhibition of adenosine deaminase has little or no influence (Huber et al., 2001); 4) AK activity is regulated in response to brain injury and is subject to developmental regulation (Studer et al., 2006; Pignataro et al., 2008). We demonstrated that AK has the same importance in the retina. In the present work, intraperitoneal injection of ABT 702 was found to cause a significant inhibition of ICAM-1 and TNF- α




Fig. 8. Inhibition of adenosine kinase is more effective than adenosine deaminase in blocking TNF- α release in activated retinal microglial cells. Retinal microglial cells were treated with AGA (500 μ g/mL, 16 h) in the presence of different doses of EHNA (ADA inhibitor), and ABT 702. TNF- α levels were determined by ELISA. Data shown are the mean \pm SD of at least four different experiments.

mRNA as well as protein levels in the retina of diabetic mice, suggesting the curative effect of ABT 702 on inflammation associated with STZ-diabetic model. ABT 702 also prevented up-regulation of Iba1;

supporting the hypothesis that ABT 702 reduces retinal inflammation through attenuation of microglia activation. Following this, we used primary culture of rat retinal microglial cells to gain insights into the




Fig. 9. Inhibition of adenosine kinase blocks TNF- α release via A_{2A} AR. Cells were treated with vehicle or ABT 702 (20 μ M) 30 min before AGA treatment in the presence of subtype-selective AR antagonists for A_1 AR (CPX, 100 nM), A_{2A} AR (ZM241385, 100 and 500 nM), A_{2B} AR (MRS 1754, 1 μ M) and A_3 AR (MRS 1523, 10 μ M). *Significant compared to AGA treated microglial cells ($P < 0.05$).

mechanism of ABT 702's anti-inflammatory effect. The results indicate that treatment of ABT 702 inhibited AGA-induced TNF- α release. Furthermore, ABT 702 was more effective than ADA inhibitor in inhibiting TNF- α release, suggesting a major role for AK in the regulation of extracellular adenosine.

The ability of ABT 702 to mitigate AGA-induced TNF- α release suggests the importance of inhibiting AK activity in ameliorating this inflammatory response through increasing adenosine levels. To test this hypothesis, the inhibitory effect of ABT 702 on AGA-induced TNF- α release was examined in the presence of AR subtype-selective antagonists in the retinal microglial cells. This inhibitory effect was successfully blocked only by 4-{2-[7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3- α] [1,3,5]triazin-5-ylamino]ethyl} phenol (ZM 241385), a selective A_{2A}AR antagonist. These results suggest that ABT 702 inhibits AGA-induced TNF- α release in retinal microglia through A_{2A}AR. A_{2A}AR mediates the suppressive effects of adenosine in macrophages as well as microglial cells (Kreckler et al., 2006).

Diabetes or inflammation is associated with up-regulation of A_{2A}AR (Pang et al., 2010). High levels of A_{2A}ARs are found in macrophages and microglial cells that are poised, on activation, to abrogate the immune response (Trincavelli et al., 2008). In addition, hyperglycemia is associated with increased ENT1, possibly via an MAPK/ERK-dependent signaling pathway (Leung et al., 2005). ABT 702 inhibited the expression of both A_{2A}AR and ENT1 in the diabetic retina suggesting its ability to attenuate diabetic conditions. Further, we demonstrated that ABT 702 injection attenuated diabetes-induced reduction in AK expression. In the brain, AK expression is decreased following onset of injury thus potentiating the adenosine surge as a potential neuroprotective mechanism. Indeed, expression levels of AK might have a crucial role in determining the degree of brain injury (Li et al., 2008).

Next, we studied the effect of ABT 702 on oxidative and nitrosative stress in the retina in diabetes. In diabetes the retina experiences increased oxidative stress (Kowluru and Kanwar, 2007), and reactive oxygen species (ROS) are considered as a causal link between elevated glucose and the metabolic abnormalities important in the development of diabetic complications (Brownlee, 2001). ABT 702 decreased superoxides and nitrotyrosine levels in diabetic retina. The ability of ABT 702 to reduce inflammatory stress in the retina may rely on its inhibitory effect on oxidative and nitrosative stress.

Further, we studied the effect of ABT 702 on retinal cell death. Diabetes-induced retinal oxidative and nitrosative stress have been positively correlated with neuronal cell death (Asnaghi et al., 2003). Treating diabetic mice with ABT 702 blocked the increases in oxidative and nitrosative stress and significantly reduced cell death as revealed by decreased cleaved caspase-3 immunostaining and TUNEL assay in treated diabetic retinas. Neurons are highly susceptible to oxidative stress, which can induce apoptosis; therefore, it is likely that diabetes-induced oxidative stress leads to neuronal injury.

Finally, despite all the advantages for ABT 702 as a potential effective therapy for DR, given that the administration of ABT 702 by i.p. injection is invasive and stressful, oral administration of ABT 702 may be necessary but should be carefully developed (Kowaluk et al., 2000).

Conclusions

The data presented here provide experimental evidence that targeting AK can inhibit diabetes-induced retinal abnormalities that are postulated in the development of DR by potentially amplifying the endogenous therapeutic effects of site- and event-specific accumulation of extracellular adenosine. Thus, ABT 702 appears to be a useful therapy to possibly inhibit the development/progression of retinopathy, the sight threatening complication faced by diabetic patients.

Conflict of interest

We have no conflict of interests.

Acknowledgments

This work was supported by Egyptian Cultural and Educational Bureau (NME and GIL), Department of Defense DM102155 (GIL) and Vision Discovery Institute (GIL).

References

- Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. *Diabetes* 2003;52:506–11.
- Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. *Trends Pharmacol Sci* 2006;27:652–8.
- Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors. *J Clin Invest* 1996;98:2779–85.
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001;414:813–20.
- El-Remessy AB, Al-Shabraway M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. *Am J Pathol* 2006;168:235–44.
- El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. *Mol Vis* 2008;14:2190–203.
- Gouder N, Scheurer L, Fritschy JM, Boison D. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. *J Neurosci* 2004;24:692–701.
- Huber A, Padrun V, Déglon N, Aebischer P, Möhler H, Boison D. Grafts of adenosine releasing cells suppress seizures in kindling epilepsy. *Proc Natl Acad Sci U S A* 2001;98:7611–761.
- Ibrahim AS, El-Remessy AB, Matragoon S, Zhang W, Patel Y, Khan S, et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. *Diabetes* 2011a;60:1122–33.
- Ibrahim AS, El-Shishtawy MM, Zhang W, Caldwell RB, Liou GI. A2A Adenosine Receptor (A_{2A}AR) as a Therapeutic Target in Diabetic Retinopathy. *Am J Pathol* 2011b;178:2136–45.
- Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee CH, Jiang M. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. *J Pharmacol Exp Ther* 2000;295:1156–64.
- Johnston-Cox HA, Ravid K. Adenosine and blood platelets. *Purinergic Signal* 2011;7:357–65.
- Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. *FASEB J* 2004;18:1450–2.
- Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. *Mol Vis* 2009;15:1418–28.
- Kern TS, Barber AJ. Retinal ganglion cells in diabetes. *J Physiol* 2008;586:4401–8.
- Kowaluk EA, Mikusa J, Wismer CT, Zhu CZ, Schweitzer E, Lynch JJ, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. *J Pharmacol Exp Ther* 2000;295:1165–74.
- Kowluru RA, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. *Nutr Metab* 2007;4:8.
- Kreckler LM, Wan TC, Ge ZD, Auchampach JA. Adenosine inhibits tumor necrosis factor- α release from mouse peritoneal macrophages via A_{2A} and A_{2B} but not the A₃ adenosine receptor. *J Pharmacol Exp Ther* 2006;317:172–80.
- Leung GP, Man RY, Tse CM. Glucose upregulates adenosine transport in cultured aortic smooth muscle cells. *Am J Physiol Heart Circ Physiol* 2005;288:2756–62.
- Li T, Ren G, Lusardi T, Wilz A, Lan JQ, Iwasato T, et al. adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. *J Clin Invest* 2008;118:571–82.
- Liou GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A_{2A} adenosine receptor. *Invest Ophthalmol Vis Sci* 2008;49:5526–31.
- Löffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological roles of vascular nucleoside transporters. *Arterioscler Thromb Vasc Biol* 2007;27:1004–13.
- Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. *Rev Endocr Metab Disord* 2008;9:315–27.
- Milne GR, Palmer TM. Anti inflammatory effects of the A_{2A} adenosine receptor. *Scientific World Journal* 2011;11:320–39.
- Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. *Blood* 2008;111:5571–80.
- Möser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. *Am J Physiol* 1989;256:799–806.
- Pak MA, Haas HL, Decking UK, Schrader J. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. *Neuropharmacology* 1994;33:1049–53.
- Pang T, Gan XT, Freeman DJ, Cook MA, Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. *Am J Physiol Heart Circ Physiol* 2010;298:545–53.

- Peart J, Matherne GP, Cerniway RJ, Headrick JP. Cardioprotection with adenosine metabolism inhibitors in ischemic-reperfused mouse heart. *Cardiovasc Res* 2001;52:120–9.
- Pignataro G, Simon RP, Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. *J Cereb Blood Flow Metab* 2007;27:1–5.
- Pignataro G, Maysami S, Studer FE, Wilz A, Simon RP, Boison D. Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. *J Cereb Blood Flow Metab* 2008;28:17–23.
- Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. *Middle East Afr J Ophthalmol* 2012;19:52–9.
- Shen HY, Lusardi TA, Williams-Karnesky RL, Lan JQ, Poulsen DJ, Boison D. Glucose upregulates adenosine transport in cultured human aortic smooth muscle cells. *J Cereb Blood Flow Metab* 2011;1648–59.
- Studer FE, Fedele DE, Marowsky A, Schwerdel C, Wernli K, Vogt K, et al. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. *Neuroscience* 2006;142:125–37.
- Suzuki R, Stanfa LC, Kowaluk EA, Williams M, Jarvis MF, Dickenson AH. The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury. *Br J Pharmacol* 2001;132:1615–23.
- Tang J, Kern TS. Inflammation in diabetic retinopathy. *Prog Retin Eye Res* 2011;30:343–58.
- Trincavelli ML, Melani A, Guidi S, Cuboni S, Cipriani S, Pedata F, et al. Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain. *J Neurochem* 2008;104:479–90.
- Ugarkar BG, Castellino AJ, DaRe JM, Kopcho JJ, Wiesner JB, Schanzer JM, et al. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. *J Med Chem* 2000;43:2894–905.
- Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. *Physiol Rev* 2006;86:901–40.
- Vlajkovic SM, Guo CX, Telang R, Wong AC, Paramanathasivam V, Boison D, et al. Adenosine kinase inhibition in the cochlea delays the onset of age-related hearing loss. *Exp Gerontol* 2011;46:905–14.
- Williams M. Challenges in developing P2 purinoceptor-based therapeutics. *Ciba Found Symp* 1996;198:309–21.
- Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, et al. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1–42-and lipopolysaccharide activated microglia. *J Neurosci* 2002;22:3484–92.
- Zhu XF, Zou HD. PEDF in diabetic retinopathy: a protective effect of oxidative stress. *J Biomed Biotechnol* 2012;580687–95.